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1. SUMMARY 
The present thesis is based on the premise that chronic heart failure patients have a high morbidity and 
mortality due to the fact that cardiac insufficiency per se evolves inexorably, and that it affects an elder and 
frail population, suffering from multiple pathologies, polymedicated and even socio-economically 
vulnerable. 
The increase of life expectancy, inherent to the improvement of health care, determined a parallel augment 
of chronic heart failure patients.  
Albeit we have assisted to a consistent decline in the rate of heart failure hospitalizations, surprisingly, short-
term readmission and mortality persist high, irrespective of clinical innovations and guideline directed 
management, representing a tremendous health care burden. 
It urges to define a short-term prognosis for these patients in order to reduce the readmission and premature 
mortality rates due to its socio-economic impact. 
The main purpose of this dissertation is to characterize at risk patients for early (defined as a period of 90 
days post-discharge) readmission, due to heart failure, and overall death. 
The putative role of biochemical cardiovascular markers in clinical decision making, principally in 
recognizing high risk patients that could benefit from therapeutic intensification and stricter surveillance is 
also addressed. 
To characterize the population we addressed disease related risk factors [namely the etiology, the New York 
Heart Association Functional (NYHA) Class, left ventricular ejection fraction (LVEF), right ventricular 
function, signs and symptoms], non-modifiable cardiovascular risk factors, modifiable cardiovascular risk 
factors, comorbidities [chronic kidney disease (CKD), anemia, iron deficiency, thyroid function], therapeutic 
and biomarkers [specifically troponins, proBNP-Aminoterminal B-type Natriuretic Peptide (NT-proBNP), 
Galectin-3 (Gal-3), Suppression of Tumorigenicity 2 (ST2), Mid-Regional pro-Adrenomedullin (pro-ADM)] 
and Erythropoietin (EPO). 
 
Key words: 
Chronic heart failure; Short-term readmission; Short-term mortality; Galectin-3; ST2. 
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2. RESUMO 
A presente tese baseia-se na premissa de que os doentes que padecem de insuficiência cardíaca crónica 
apresentam uma morbilidade e mortalidade elevadas fruto da evolução per se inexorável da insuficiência 
cardíaca e do facto de afetar uma população maioritariamente idosa, frágil, que sofre de múltiplas 
patologias, polimedicada e, inclusive, socioeconomicamente desprovida. 
O aumento da esperança de vida, inerente à melhoria dos cuidados de saúde, determinou um incremento 
paralelo da prevalência da insuficiência cardíaca crónica. 
Apesar de se ter assistido a um declínio das taxas de internamento por insuficiência cardíaca, 
surpreendentemente, as taxas de reinternamento e mortalidade precoces mantêm-se elevadas, 
independentemente dos avanços clínicos e abordagem em conformidade com as directrizes preconizadas, 
sobrecarregando tremendamente o sistema de saúde. 
Atendendo ao seu impacto socioeconómico urge definir o prognóstico a curto prazo destes doentes a fim de 
reduzir a taxa de readmissão e mortalidade precoces. 
Trata-se de um estudo de coorte prospetivo observacional, unicêntrico, com um único braço, de utilidade 
diagnóstica. 
O objetivo principal do estudo foi caracterizar os doentes de risco para readmissão e mortalidade precoces 
(definido como o período até 90 dias pós-alta) por insuficiência cardíaca. 
Apesar do propósito deste estudo ser, primeiramente, definir o prognóstico a curto prazo da insuficiência 
cardíaca, o seguimento prolongado permitiu-nos caracterizar, também, a mortalidade a longo prazo. 
Consideramos a mortalidade global atendendo a que a maioria dos doentes não faleceu no hospital, pelo que 
não tivemos acesso às certidões de óbito. 
O objetivo secundário foi avaliar a importância de biomarcadores emergentes no prognóstico da 
insuficiência cardíaca. 
Para caracterizar a população abordamos fatores de risco relacionados com a insuficiência cardíaca per se 
(nomeadamente a etiologia, a classe funcional da NYHA, a fração de ejecção do ventrículo esquerdo, a 
função do ventrículo direito, sinais e sintomas), fatores de risco cardiovasculares não-modificáveis, factores 
de risco cardiovasculares modificáveis, comorbilidades (tais como a doença renal crónica, a anemia, a 
deficiência de ferro, a função tiroideia), a terapêutica e biomarcadores (troponinas, NT-proBNP, galectina-3, 
ST2, pro-ADM e EPO). 
 
Os critérios de inclusão foram:  
 admissão por insuficiência cardíaca classe III ou IV de NYHA; 
 idade igual ou superior a 18 anos. 
Os critérios de exclusão foram:  
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  óbito no primeiro internamento; 
  alta contra-parecer médico; 
  doença renal crónica com uma taxa de filtração glomerular <30 ml/min/1.73 m2 [calculada através da 
fórmula Modification of Diet in Renal Disease (MDRD)] ou sob técnica de substituição renal; 
  doença hepática moderada a grave; 
  neoplasia ativa com ou sem metástases. 
Foram recrutados 70 doentes dos quais 5 foram excluídos por lhes ter sido diagnosticado neoplasia ativa. 
O recrutamento teve a duração de 12 meses, começando (primeiro participante) a 19/11/2015. 
Os participantes foram seguidos até 30/09/2017 ou até à data de óbito. 
Todos os participantes assinaram um consentimento informado. 
Os métodos estatísticos utilizados foram: 
Análise Descritiva:  
As varáveis contínuas foram sumarizadas por média, mediana, desvio padrão, 1º e 3º quartis, intervalo 
interquartil e mínimo/máximo. 
A comparação entre pacientes foi realizada para todas as variáveis utilizando o t test ou o Wilcoxon Rank 
test conforme aplicável. 
As variáveis categóricas foram sumarizadas por frequências relativas e absolutas, e comparadas mediante o 
teste qui quadrado ou o teste exacto de Fisher, conforme aplicável. 
Consideraram-se como variáveis de estratificação: 
  a readmissão precoce; 
  a mortalidade precoce; 
  mortalidade a longo prazo. 
Utilizou-se o Shapiro-Wilk test para avaliar a normalidade das variáveis contínuas. 
 
Análises de Objetivos Primários: 
Para se avaliar os objetivos primários deste estudo, efectuou-se uma análise de sobrevivência para cada um 
dos pontos de interesse (i.e. readmissão precoce, mortalidade precoce e mortalidade a longo prazo), 
utilizando curvas de sobrevivência de Kaplan Meier. 
Aplicou-se o teste Log rank para comparar probabilidades de sobrevivência para cada uma das referidas 
variáveis. 
Um modelo univariável de Cox (proporcionalidade das funções de risco) foi usado para se obter Hazard 
Ratios (HR) e intervalos de confiança de 95% para cada variável. 
Utilizaram-se os resíduos de Schoenfeld para testar os hazards proporcionais. 
Todas as análises foram conduzidas com um nível de significância global de 5%. 
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Não se efetuou imputação de dados em falta. 
Não se fizeram ajustes para multiplicidade. 
Toda a análise estatística foi realizada com o programa R Statistical Software version 3.4.3. 
Atendendo a que alguns dos biomarcadores estudados não têm cut-offs definidos utilizou-se a Area Under the 
Curve Receiver-Operator Characteristic (AUCROC) conforme definida por Hand e Till. 
O cut-off adequado para cada biomarcador foi definido usando o Índice de Youden. 
Da análise estatística concluiu-se que o seguimento mediano foi de 13.7 (6.7-18.9) meses. 
A idade média da população estudada foi 79.2 ±10.8 anos. 
A amostra foi constituída maioritariamente por participantes do sexo feminino (56.9%). 
Salientamos que a fração de ejecção média foi de 50.38 ± 19.07 %. 
A taxa de readmissão aos 30 dias pós-alta foi de 15.4% e aos 90 dias de 33.8%, em sintonia com dados 
nacionais. 
A mortalidade aos 30 dias pós-alta foi de 10.8% e aos 90 dias de 18.5%, também de acordo com a literatura. 
Destacamos que a mortalidade anual foi de 36.9% e no fim do seguimento [mediana 13.7 (6.7-18.9) meses] 
40% dos participantes tinha perecido. 
Estes dados espelham a gravidade clínica dos doentes que padecem de insuficiência cardíaca. 
O internamento médio foi de 8.3 dias, o que, também, reflecte a complexidade dos casos abordados. 
Os doentes com vários internamentos, com maior número de dias de internamento acumulado e com 
internamentos prolongados tiveram pior prognóstico. 
De acordo com os resultados obtidos, o doente de risco para readmissão e morte no período crítico dos 90 
dias após alta, é idoso e sofre de várias comorbilidades, nomeadamente doenças metabólicas. 
Curiosamente, a obesidade correlacionou-se com um melhor prognóstico. 
Das várias comorbilidades de que padecem os doentes com insuficiência cardíaca, verificamos que a 
insuficiência renal se correlacionou com todos os objetivos primários visados. 
Salientamos que a síndrome cardiorenal tipo 1 determinou um risco acrescido de mortalidade precoce e a 
longo prazo. 
A anemia e a ferropenia absoluta condicionaram o prognóstico, sendo que valores elevados do estimulador 
da hematopoiese, eritropoeitina, se correlacionaram com a mortalidade precoce e a longo prazo. 
O índice de dispersão eritrocitário, frequentemente negligenciado na estratificação do risco do doente com 
insuficiência cardíaca, apresentou-se como um interessante preditor de mau prognóstico para a readmissão e 
mortalidade precoces e para a mortalidade tardia. 
A fracção de ejecção do ventrículo esquerdo revelou-se um preditor de mortalidade a longo prazo nos 
doentes com fracção de ejeção reduzida, e apresentou uma tendência para a readmissão e mortalidade 
precoces no mesmo subgrupo. 
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A avaliação de elementos ecocardiográficos (pressão sistólica da artéria pulmonar, excursão sistólica do 
plano do anel tricúspide e ausência de colapso da veia cava inferior) permitiu a identificação de uma relação 
entre disfunção sistólica do ventrículo direito e pior prognóstico. 
Estes dados corroboram a impressão que apesar da importância lapidar da função do ventrículo esquerdo, a 
avaliação da função ventricular direita acrescenta informação valiosa para a estratificação do risco dos 
doentes com insuficiência cardíaca. 
Potenciais causas de hipoperfusão, tais como a hipotensão sistólica e diastólica foram marcadores de mau 
prognóstico para mortalidade precoce e a longo prazo. 
O péptido natriurético NT-proBNP, apontado na literatura, essencialmente, como adjuvante no diagnóstico, 
destacou-se como um preditor fidedigno de mortalidade precoce e a longo prazo, por correlação positiva. 
A troponina ultra-sensível (hsTnT) revelou-se um preditor de mortalidade a longo prazo, por correlação 
positiva, e quando associada a valores elevados de NT-proBNP agravou o risco de readmissão precoce.  
Ressalvamos que os biomarcadores supracitados, quando avaliados por separado não se correlacionaram 
com a readmissão precoce, mas a aferição conjunta ditou um risco acrescido desse objetivo primário. 
A Gal-3 foi um marcador de mau prognóstico para a readmissão e mortalidade precoces e para a mortalidade 
tardia. 
Quanto ao ST2 foi um preditor de mortalidade a longo prazo. 
Não se estabeleceu qualquer relação com significado estatístico com a pro-ADM, possivelmente pelo facto 
da amostra ser relativamente pequena. 
Cremos que o nosso estudo poderá contribuir para a definição do doente de risco com insuficiência cardíaca 
no período crítico dos 90 dias após a alta clínica. 
 
Palavras-chave: 
Insuficiência cardíaca crónica; Readmissão precoce; Mortalidade precoce, Galectina-3; ST2. 
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3. ABBREVIATIONS AND ACRONYMS 
ACC - American College of Cardiology 
ACE - Angiotensin-Converting-Enzyme 
ADHF - Acute Decompensated Heart Failure 
ADQI - Acute Disease Quality Initiative 
AF - Atrial Fibrillation 
AHA - American Heart Association 
ARB - Angiotensin Receptor Blocker 
AUC - Area Under the Curve 
BB - Beta Blocker 
BMI - Body Mass Index 
BNP - B-type natriuretic peptide 
CHF - Chronic Heart Failure 
CI - Confidence Interval 
CKD - Chronic Kidney Disease 
cTnI - Cardiac Troponin I 
cTnT - Cardiac Troponin T 
CV - Cardiovascular 
EAS - European Atherosclerosis Society  
ECG - 12-lead electrocardiogram 
EDTA - Ethylenediaminetetraacetic Acid 
ELISA - Enzyme-Linked Immunosorbent Assay 
EPO - Erythropoietin 
ESC - European Society of Cardiology 
ESH - European Society of Hypertension 
FT3 - Free Triiodothyronine 
FT4 - Free Thyroxine 
Gal-3 - Galectin-3 
GFR - Glomerular Filtration Rate 
HR - Hazard Ratio 
HF - Heart Failure 
HFSA - Heart Failure Society of America 
HFmrEF - Heart Failure with Mid-Range Ejection Fraction 
HFpEF - Heart Failure with Preserved Ejection Fraction 
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HFrEF - Heart Failure with Reduced Ejection Fraction 
hsTnT - Highly Sensitive Troponin T 
IDF - International Diabetes Federation 
IL - Interleukin 
LBBB - Left Bundle Branch Block 
LV - Left Ventricular 
LVEF - Left Ventricular Ejection Fraction 
MR-proADM - Mid-Regional pro-Adrenomedullin 
MRA - Mineralocorticoid Receptor Antagonist 
NPV- Negative Predictive Value 
NT - proBNP- Aminoterminal B-type Natriuretic Peptide 
NYHA - New York Heart Association 
PASP - Pulmonary Artery Systolic Pressure 
PPV - Positive Predictive Value 
RBBB - Right Bundle Branch Block 
RDW - Red Cell Distribution Width 
ROC - Receiver-Operator Characteristic 
SD - Standard Deviation 
ST2 - Suppression of Tumorigenicity 2 
TAPSE - tricuspid annulus plane systolic excursion 
TSH - Thyroid Stimulating Hormone 
USA - United States of America 
WHO - World Health Organization 
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4. INTRODUCTION 
The current European guidelines define heart failure (HF) as an alteration of the cardiac structure or function 
resulting in a deficient oxygen intake to the tissues, despite adequate filling pressures (or solely at expenses 
of high filling pressures), which is clinically characterized by a constellation of symptoms and typical signs.
1 
It is estimated that around 15 million europeans
2 
and 6 million americans
3
 suffer from chronic heart failure 
(CHF), moreover the prevalence is superior to 10% in the population over 70 years of age.
4
 
Although we have witnessed a decrease in hospitalization due to CHF of about 30.5% in the last decade, the 
rehospitalization rate dropped just 9.7% in the same time period.
5,6
 
Up to 25% of patients with HF are readmitted in the first 30 days after hospital discharge
7,8
 and 
approximately 30% are readmitted 60 to 90 days post-discharge
9,10
 despite management consentaneous with 
the preconized guidelines and evidence based, diagnostic advances, innovative drugs and new therapeutic 
devices. 
Adding to this matter is the mortality rate 60 to 90 day post-discharge of about 15%.
8 
Decompensated HF requiring hospitalization is a serious condition which progresses with high mortality and 
high readmission rates. 
Strikingly, the 10-year mortality for patients newly admitted with HF is estimated to be around 100%.
11
  
Due to its poor outcome, HF could be considered a “malignant condition”.12  
Patients with HF are mostly elderly, with multiple comorbidities, namely metabolic diseases, and are 
polymedicated, showing a readmission and mortality rate at 90 days of discharge, respectively 8 and 11 
times higher than the general population.
13
 
Most of these diseases are both the primum movens and independent risk factors, as HF etiology determines 
its prognosis.  
According to the Prevalence of Chronic Heart Failure in Southwestern Europe (EPICA) trial, the estimated 
prevalence of CHF, in Portugal, between the ages of 20 and 50 is 1.36%, peaking to 16% in the population 
older than 80 years.
14,15 
The EPICA investigators also found that two-thirds of HF patients are hospitalized, in average, twice in a 
year and that 20 to 30% are readmitted within three months of hospital discharge.
14,15
  
Given the complexity and prevalence of the HF syndrome, it is mandatory to discriminate high risk patients 
that can benefit from a thorough assessment and define effective diagnosis and prognosis strategies. 
Early readmissions are mainly related with volume overload, while later rehospitalizations are the 
consequence of the inexorable progression of this syndrome, which is inherently linked to cardiac 
remodeling. 
16 
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Ergo, the first three months post-discharge are crucial in HF’s evolution, and since the short-term prognosis 
has failed to improve over the past decade despite updated management, one should intervene assertively in 
this golden period. 
The novel biochemical markers emerge as promising tools that can complement traditional clinical practice. 
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5. FUNDAMENTALS 
A policy statement from the American Heart Association (AHA) underlines that the number of HF patients is 
expected to duplicate until 2030 and consequently its social impact.
17  
Hospitalization for HF represents a major burden on healthcare services worldwide, and is a strong predictor 
of increased mortality, particularly, in the first months post-discharge.
18  
Heart failure is the leading cause of admission in Europe and in the United States of America (USA), 
accounting for 1 to 2% of all hospitalizations.
16 
Furthermore, around 30% of these patients require rehospitalization within 60 to 90 days.
19  
The National Heart Failure Audit of almost 57 000 hospitalizations in England and Wales, from 2014 to 
2015, showcased an in-hospital mortality of 9.6%, a 30-day mortality of nearly 20% and a mortality at one 
year of 30%. Unfortunately, the reported rates did not improve for the past six years.
20 
Despite the socio-economic relevance that the characterization and acknowledgement of rehospitalizations 
due to HF may yield, national trials focusing this topic are scant, thus this study could render a little 
contribution to this matter.  
The EPICA trial, dating from 2002, is the only Portuguese HF prevalence study, so, given the substantial 
social, economic and cultural changes in our country in the past two decades it is crucial to understand the 
new trends of this overwhelming syndrome. 
The Portuguese Consensus Statement for the improvement of HF, released in 2017, recognized that, 
regardless of HF prevalence, general population and politicians are not aware of its social importance.
21 
 
The EPICA study estimated a 4.36% HF global prevalence, varying from 1.36% between the ages of 25-49, 
to 16.14% in the population over 80 years of age. 
However, the ageing of the population led to an inevitable increase in HF’s prevalence, and based on the 
2011 Portuguese Census, there is an estimated 380 000 HF patients in Portugal.
22  
Relying on recent Portuguese Health System official data, HF as the primary diagnosis represents the second 
highest hospital burden, being responsible for 182 512 hospitalization days corresponding to 18 588 patients, 
with a mean hospital stay of 9.8 days and an in-hospital mortality of 12.5%.
23 
Still, these numbers are underestimated as HF is often neglected when classified as a secondary diagnosis.
24 
From 2004 to 2012 the number of HF admissions in Portugal increased 33% and the readmission rate, 
especially at 30 (14.6%) and 60 days, also rose.
25 
Twenty years ago HF hospitalizations in Portugal represented a sum of around 24 million euros, nowadays 
the economic impact is surely higher given its increasing prevalence and prolongation of HF patients’ 
survival.
26 
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5.1. THE IMPACT OF CHRONIC HEART FAILURE READMISSIONS 
The increase in life expectancy generated what probably is the greatest challenge in modern medicine: to 
prolong the quantity of life while preserving the quality of life.
27
  
The evolution towards chronicity of the most prevalent illnesses in the western world, and the consistent 
increase of survival in patients with chronical illnesses implies, inevitably, an enhanced hazard of 
readmissions due to acute decompensation.
 
Ageing of the population due to the prolongation of life span of patients with chronic conditions, inherent to 
the improvement in health care, has led to an increase in the prevalence of HF, making this disease a major 
and growing public health problem. 
According to the latest European guidelines, HF has an estimated prevalence of 1 to 2% in the adult 
population. The percentage of HF patients increases with age, affecting at least 10% of the individuals aged 
70 years or older.
1 
The acute pathologies, with emphasis towards infectious diseases, exacerbation of comorbidities, non-
compliance to evidence-based therapies, clinical inertia/ patient under-treatment, complications associated to 
treatment, the inevitable evolution of some chronic diseases, the clinical and socio-economical fragility of 
the more advanced age groups, represent the main causes of chronic disease decompensation.   
Acknowledging the precipitants of chronic illnesses decompensation, describing risk factors correlated to 
hospital readmission is fundamental. 
Hospital readmission entails an expenditure of resources, being considered a quality parameter of the 
provided healthcare.
28 
High readmission rates translate into an increase in hospital expenses, a decline in provided care quality and 
are related to high hospital mortality percentages.
29 
In-hospital mortality rates are greater in readmitted patients, given the fact that readmissions often represent 
more severe clinical scenarios.
30 
The definition of hospital readmission is not consensual, determining great disparity among series (the 
percentage of readmissions in the USA for adult individuals varies between 5% and 29%).
30  
Readmission is defined as a new hospitalization occurring in a period of 1, 2, 4 or 12 months after 
discharge.
31
 
 
Regardless of the generalized use of the readmission rate to ascertain the quality of healthcare, there is 
evidence that maybe it is not a reliable evaluation criterion.
32 
Such occurs due to the multiplicity of conditionings that envelop readmission. 
Apart from patient characteristics, such as age, gender, comorbidities,
29 
hospital characteristics affect as well 
the readmission rate.
33 
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Ansari et al., divulged that central hospitals have a higher readmission rate, since by being more specialized, 
receive more complex patients and with higher clinical severity, hence more prone to being readmitted.
34 
Kossovsky et al., disclosed that HF readmissions would be more related to the clinical and demographics 
characteristics rather than hospital care quality.
35 
A study addressing the same issue did not find a correlation between this parameter and hospital provided 
care.
36 
The understanding of the determining factors for rehospitalizations may contribute to outline strategies 
capable of reducing readmissions and consequently the costs related to healthcare.
37 
The identification of hospital readmission risk factors may improve, as well, the performance of healthcare 
practitioners and therefore the prognosis of chronic patients. 
 
5.2. THE IMPORTANCE OF BIOMARKERS 
Clinical judgement, the cornerstone of medical praxis is enhanced by imaging and biological diagnostic 
tests.  
Eugene Braunwald, a decade ago, produced a meticulous review addressing the increasing importance of 
biomarkers in the management of HF, anticipating a multi-marker strategy for HF risk stratification.
38 
Since then, scientific advance has brought us several physiopathological biomarkers of HF.
 
Despite its undisputed utility, most of these biomarkers are expensive and are not available in most 
laboratories which limit its application in a daily basis. 
Besides, some lack a well-consolidated threshold. 
Multiple cardiovascular disorders provoke myocyte sustained injury leading to cardiac remodeling which 
stimulates proliferation of interstitial fibroblasts and biosynthesis of extracellular matrix components, 
culminating in cardiac fibrosis. 
Beyond its diagnostic, prognostic and, eventual, therapeutic monitoring use, many researchers have explored 
its value in the inhibition of cardiac remodeling, raising the possibility of novel therapeutic targets. 
The overwhelming amount of data exploring this topic favors natriuretic peptides as the most reliable 
diagnostic predictors. 
Nonetheless, promising novel biomarkers, namely galectin-3, mid-regional pro-adrenomedullin and ST2 
seem to be superior to the traditional natriuretic peptides concerning prognosis. 
Furthermore, a multi-marker strategy appears to yield additional information, as current data alludes a 
synergism between natriuretic peptides and the cited biomarkers. 
Biologic markers allow quantification of certain physiopathological processes.
39 
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Ideally, a marker should fulfill the following criteria: accuracy warranting a precise identification of at risk 
subjects; reliability which represents the ability of reproducing consistently the results; and therapeutic 
importance with early intervention.
40 
The vast consistent data addressing emerging cardiac fibrosis markers as adjunctive to conventional clinical 
risk factors and natriuretic peptides dosing, led the American College of Cardiology (ACC)/ American Heart 
Association to grant ST2 and Gal-3 evaluation a class II recommendation for CHF prognosis, in 2013.
41
 
Heart failure management through biological markers is based on the assumption that variations over time 
reflect clinical improvement or disease progression. Yet, translating analytical data to clinical practice is 
complex.
42
 
When it comes to biomarker interpretation two variables should be taken into account: the analytical 
variability (inaccuracy of the test) and the biological variability (anticipated variability within a person over 
time).
43 
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6. METHODS 
6.1.  STUDY POPULATION 
6.1.1. RECRUITMENT, ENROLLMENT PERIOD, AND SAMPLE SIZE 
The study was conducted in the Department I of Internal Medicine of the Santa Maria University Hospital, 
with the approval of the Academic Medical Center Ethics Committee. (Attachment I) 
The study enrolled 70 patients admitted to ward with acute heart failure NYHA class III and IV, recruited 
over a planned recruitment period of 12 months, starting (first subject) on 19/11/2015. 
Ages eligible for study: 18 years and older.  
Genders eligible for study: both. 
All patients enrolled were followed until 30/09/2017 or date of death (whichever occurred first). 
6.1.2. INCLUSION CRITERIA 
Patients admitted with acute decompensated heart failure in class III or IV of NYHA. 
Written informed consent was requested to all eligible patients. (Attachment II) 
6.1.3. EXCLUSION CRITERIA  
 in-hospital death in the first hospitalization; 
 hospital discharge against medical advice; 
 chronic kidney disease patients with a glomerular filtration rate (GFR) <30 ml/min/1.73 m2 (calculated 
with the MDRD score) or under kidney substitution technique; 
 moderate or severe hepatic impairment (calculated with the Child-Pugh score); 
 active neoplasm with or without metastasis. 
 
6.2. STUDY DESIGN  
6.2.1. STUDY DESIGN 
Observational prospective cohort, single-center, single-arm, diagnostic utility study. 
6.2.2. ENDPOINTS 
Primary endpoints:  
Characterize at risk patients for early readmission due to heart failure (defined as readmission up to 90 days 
post-discharge) and for short-term mortality (defined as death occurred within 90 days post-discharge). 
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We considered all-cause mortality given that most of the patients did not die in the hospital and, therefore, 
we did not have access to the death certificates. 
 
Secondary endpoints:  
Assess the importance of new cardiovascular risk biomarkers (such as Gal-3, ST2, Pro-ADM and EPO) in 
the prognosis of cardiac insufficiency namely early readmission due to heart failure, overall short-term 
mortality and overall long-term mortality.  
 
Although the purpose of this study was primarily to define short-term heart failure outcome, the extended 
follow-up allowed us to characterize long-term mortality. 
 
6.3. STUDY PROCEDURE 
6.3.1. STUDY PATIENTS 
The study encompassed patients admitted to ward with acute decompensated heart failure NYHA class III 
and IV. 
Patient assessment was based on a protocol that included clinical history, physical examination, 12-lead 
electrocardiogram (ECG), thoracic X-ray, blood sampling for laboratory tests, transthoracic Doppler 
echocardiography and therapeutic data. (Attachment III) 
6.3.2. MASKING  
The author was blinded for the measurements of the biomarkers since the results were only acknowledged at 
study completion. 
It is an observational study as there was no interference in clinical decisions. 
Protocol´s laboratory tests, ECG, thoracic X-ray and transthoracic Doppler echocardiography were 
performed as per routine clinical practice. 
6.3.3. EXAMS 
A postero-anterior chest X-ray was performed with a conventional equipment to the studied population. 
A 12 lead ECG was executed using a 3 channel conventional equipment, and its interpretation was based on 
the American Heart Association Electrocardiography and Arrhythmias Committee criteria (vide Protocol).  
All echocardiograms M mode, two-dimensional and Doppler were performed by an experienced operator. 
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Using a Hitachi Aloka alfa 6 Medical device with a 2.5 MHz transducer, an echocardiographic examination 
was made with the subject lying in the left lateral recumbent position. The parasternal long and short axis, 
and the apical four- and two-chamber views were observed. 
Aortic, tricuspid and pulmonary transvalvular flows were also collected. 
The segmental contractility was obtained using a 16 segments model and echocardiographic values were 
determined in accordance with the American Society of Echocardiography (vide Protocol). 
Left ventricular (LV) volumes were calculated by the biplane Simpson method, performing manual 
planimetry of the left ventricle endocardial contour area, at the insertion of the mitral valve cusps to the 
apex, in systole and diastole. 
Diastolic function evaluation was estimated through the observation of mitral transvalvular curves, based on  
E and A wave velocity and  deceleration time; tissue Doppler was applied to record mitral annular velocities 
at the septal and lateral sides of the annulus. E/E`ratio was determined. Left atrial maximal volume index 
was calculated. 
Pulmonary artery systolic pressure (PASP) was quantified through tricuspid regurgitant flow. 
A subcostal evaluation of the inferior vena cava was also performed. 
6.3.4. BLOOD SAMPLES  
Biomarkers were measured using plasma samples.  
Plasma samples were stored at the study sites at -20ºC, followed by storage at -80ºC.  
Galectin-3, ST2/IL-33R, mid-regional pro-adrenomedullin and erythropoietin were quantified in plasma 
using pre-coated human ELISA kits (galectin-3, ST2/ Interleukin (IL)-33R and erythropoietin with R&D 
Systems, Abingdon, USA and mid-regional pro-adrenomedullin with Elabscience Biotechnology Co., Ltd).  
The reference range for galectin-3, ST2/IL-33R, mid-regional pro-adrenomedullin and erythropoietin were 
0.3-10 ng/mL, 31.3-2000 pg/mL, 15.625-1000 pg/mL and 2.5-200 mIU/mL, respectively; and the minimum 
detectable amounts was 0.085 ng/mL, 13.5 pg/mL, 9.375 pg/mL and 0.6 mIU/mL, respectively.  
Plasma hsTnT levels were measured by electrochemiluminescence immunoassay Elecsys Troponin T high 
sensitive (limit of detection: 5 ng/L), Roche Diagnostics, GmbH, Mannheim, Germany.   
Plasma NT-proBNP values were measured using electrochemiluminescence immunoassay Elecsys NT-
proBNP (measuring range: 5-35,000 ng/L) Roche Diagnostics, GmbH, Mannheim, Germany.  
Biochemical parameters related to Cardiac Troponin I (cTnI), renal, hepatic and thyroid function, ionogram 
and iron kinetics were evaluated using the same plasma sample. 
Haematological values were determined using Ethylenediaminetetraacetic Acid (EDTA) whole blood.   
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6.4. DATA COLLECTION INSTRUMENTS 
Data was collected in an Excel database. 
 
6.5. STATISTICAL METHODS 
6.5.1. STUDY ENDPOINTS 
This study has 3 primary endpoints directly associated with each of the primary objectives as presented and 
defined below: 
 
Endpoint Baseline Censoring 
 
 
 
 
Early Readmission 
 
Definition 
Patient rehospitalization less than 
90 days after a hospitalization 
discharge. 
 
 
First observation (hospitalization) of each 
patient in which an early rehospitalization 
occurred after discharge (i.e. the patient was 
rehospitalized less than 90 days afterwards). 
 
For subjects without early rehospitalization 
events, the baseline (first observation) was 
considered. 
 
It was also decided to consider the baseline 
data for subjects who did not have any early 
rehospitalization event after the baseline, but 
for whom the baseline was an early 
rehospitalization itself. In those cases, the 
subject was considered as having the event, 
and the time to event (used during survival 
analysis) was calculated based on the last 
hospitalization dates. 
For subjects not having an 
early readmission event, 
censoring criteria was defined 
as 90 days. 
 
Early Mortality 
 
Definition 
Patient died less than 90 days after 
a hospitalization discharge. 
 
 
Last observation (hospitalization) of each 
patient before the early mortality event took 
place. 
 
For subjects that did not suffer early death 
event, the baseline (first observation) was 
considered. 
For subjects not having early 
mortality event, censoring 
criteria was defined as 90 days. 
Long-term Mortality 
 
Definition 
Patient died during follow-up. 
Baseline (first observation) was considered 
for all patients. 
For subjects alive by the end of 
the study, censoring criteria 
was defined as “End of study” 
date (30/09/2017). 
 
Table 1 - Primary endpoints 
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6.5.2. GENERAL STATISTICAL METHODS 
6.5.2.1. Descriptive Analysis 
Unless specified otherwise, continuous variables were summarized by mean, standard deviation (SD), 
median, 1st and 3rd quartiles, interquartile range and minimum/maximum. Comparison between patients 
with and without each of the events was performed for all variables using t test or Wilcoxon Rank test as 
applicable. Categorical variables were summarized by relative and absolute frequencies, and compared using 
chi-squared test or Fisher’s Exact test as applicable.  
The following were considered as stratification variables for: 
 Early readmission; 
 Early mortality; 
 Long term mortality 
Shapiro-Wilk test was used to assess the normality of continuous variables.  
 
6.5.2.2. Analysis of Primary Endpoints 
For the analysis of the primary endpoints of this study, a survival analysis was performed for each of the 3 
events of interest (i.e. early rehospitalization, early mortality and long-term mortality). For each endpoint, 
Kaplan Meier survival estimates were calculated and plotted for each categorical variable. Log rank test was 
used to compare survival probabilities in each of the considered variables. A univariate Cox proportional 
hazards model was fitted to the data to obtain HR and 95% confidence intervals for each variable. The 
proportional hazards assumption was tested using Schoenfeld residuals. 
All analyses were conducted at an overall significance level of 5%. No imputation was performed on 
missing data. No adjustment for multiplicity was performed. 
All statistical analyses were conducted using R Statistical Software version 3.4.3. 
 
6.5.3. BIOMARKERS’ CUT-OFF  
To be able to analyse the prognosis capabilities of each biomarker and using multiple biomarkers at the 
same time, specific cut-offs for each of them were needed. Since there are no standardized cut-offs defined 
for most of these biomarkers, the multiclass AUCROC as defined by Hand and Till was used to assess the 
overall performance of each biomarker as a predictor of each of the events of interest (i.e. early 
rehospitalization, early mortality and long-term mortality). Due to the low number of subjects, to be able to 
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calculate some viable cut-offs, it was decided to use cut-offs calculated for biomarkers with AUCROC 
above 0.7 and 95% confidence intervals (CI) significantly different from 0.5 (i.e. not containing 0.5). 
The optimal cut-off value for each biomarker to predict each of the events was defined using the Youden 
Index, which maximizes the sensitivity and specificity of the predictor. Negative predictive values (NPV) 
and positive predictive values (PPV) were calculated and reported for the selected cut-offs. 
 
6.6. COMPLIANCE STATEMENTS 
6.6.1. GENERAL REQUIREMENTS 
The study was performed in conformity with its protocol, the Declaration of Helsinki and the Oviedo 
Convention. The study was approved by the Faculty of Medicine of the University of Lisbon Academic 
Medical Center Ethics Committee.  
6.6.2. SUBJECT INFORMATION AND INFORMED CONSENT 
Subjects or legal surrogates were informed orally and in written about the purposes of the study, study 
procedures and potential risks.  
Before any study-related activities were initiated, the subjects or legal proxies signed the written informed 
consent.  
The participation in the study was entirely voluntary.  
The subjects have the right to withdraw their willingness to participate in the study at any time without 
affecting their future medical care in any way. 
6.6.3. CLINICAL STUDY RESULTS AND PUBLICATION 
The results of the study are documented in the present dissertation and, if possible, will be published (e.g. in 
scientific journals and/or presented in scientific meetings). 
6.6.4. DATA CONFIDENTIALITY AND DATA PROTECTION 
Auditors, Ethics Committee, and the regulatory authorities will be granted access to the subjects’ medical 
records to the extent permitted by the applicable law and regulation for verification of clinical study 
procedures, and/or data control, ensuring subject data confidentiality.  
The participants’ file and the source data will be archived in line with national and international legal 
requirements. 
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7. DEFINITIONS  
Arterial Hypertension was defined according to the European Society of Hypertension (ESH)/ European 
Society of Cardiology (ESC) Guidelines and/or taking hypertensive medication).
44 
Diabetes was defined following the International Diabetes Federation (IDF) criteria and/or use of antidiabetic 
drugs.
45  
Dyslipidemia was defined in accordance with the European Atherosclerosis Society (EAS) and the ESC 
Guidelines and/or use of lipid-lowering medication.
46 
Obesity was defined as body mass index (BMI) ≥30 kg/m2 (calculated as weight divided by height 
squared)].
47
  
Tabagism was defined as having ever smoked at least 100 cigarettes in the lifetime.
48
  
Glomerular filtration rate was estimated using the MDRD formula.
49 
Cardiorenal syndrome type I was defined as an acute worsening of cardiac function leading to acute kidney 
injury (defined by an increase in serum creatinine of  ≥0.3 mg/dL) in accordance to the 7th Acute Disease 
Quality Initiative (ADQI) Consensus Conference.
 50 
Anemia was defined according to the World Health Organization (WHO) as hemoglobin <13 g/dL in men 
and <12 g/dL in women.
51 
Iron deficiency associated to CHF is defined, by the ESC and the AHA/ACC/ Heart Failure Society of 
America (HFSA), as absolute (when ferritin <100 µg/L) and as functional (if ferritin is between 100-300 
µg/L with a transferrin saturation <20%).
1,52 
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8. RESULTS 
8.1. BASELINE CHARACTERISTICS 
From the 70 selected patients 5 were excluded given that during follow-up they were diagnosed with active 
cancer. 
Based on the study protocol over 200 variables were extracted and analyzed resulting in an overwhelming 
amount of data.    
To facilitate the interpretation of the results only the population characteristics considered primordial are 
described (Table 1). 
This study included 65 patients who matched the selection criteria and had a median follow-up period of 
13.7 (6.7-18.9) months.  
The mean age of the patients was 79.2 ± 10.8 years, 56.9% were female, and their mean Left Ventricular 
Ejection Fraction (LVEF) was 50.38 ± 19.07 %. 
8.1.1. READMISSIONS 
From the 65 patients that full-filled inclusion criteria, 33.8% were rehospitalized within 90 days post-
discharge, 13.8% of which in the first 30 days after discharge. 
In our study 32.4% of women were readmitted precociously versus 35.7% of men. 
The year readmission percentage was 61.5%. 
8.1.2. MORTALITY 
The 30-day mortality prevalence was 10.8% and the 90-day mortality prevalence was 18.5%. 
A trend towards compromised short-term survival and age ≥90 years was noted in the Heart Failure with 
Preserved Ejection Fraction (HFpEF) group (HR: 6.632, 95% CI: 0.599-73.409, P-value=0.123).  
Short-term mortality was similar between genders (18.9% for the females versus 17.9% for the males) but 
men showed a greater percentage of long-term death (42.9% versus 37.8%). Nevertheless, none of these 
differences were statistically significant. 
Figure 1 represents the Kaplan Meier long-term mortality curve between genders. 
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Figure 1 - Long-term mortality - Kaplan Meier: Gender 
 
The year mortality was 36.9% and 40% of patients deceased at the end of follow-up. 
 
8.2. DISEASE RELATED DETERMINANTS  
8.2.1. HOSPITALIZATIONS 
The accumulated length of stay represented a risk factor for short-term HF readmission in the general 
population study (HR: 1.022, 95% CI: 1.009-1.036, P-value<0.001). 
The number of hospitalizations was related with short-term readmission in the general population 
(HR: 1.543, 95% CI: 1.224-1.945, P- value<0.001) and in the Heart Failure with Mid-Range Ejection 
Fraction (HFmrEF) subgroup (HR: 2.814, 95% CI: 1.075-7.365, P- value=0.035) and expressed a trend 
towards greater risk in the HFpEF subgroup (HR: 1.391, 95% CI: 0.989-1.956, P- value=0.058).  
In patients suffering from Heart Failure with Reduced Ejection Fraction (HFrEF) early readmission 
risk, derived from the accumulated length of stay, was slightly superior to that of the general 
population (HR: 1.029, 95% CI: 1.008-1.050, P-value=0.006).  
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For the same group a trend towards the length of stay for a given hospitalization and early readmission was 
met (HR: 1.173, 95% CI: 0.985-1.395, P-value=0.073) and another trend was found between the number of 
hospitalizations and early readmission (HR: 1.560, 95% CI: 0.997-2.442, P-value=0.052). 
A trend towards the accumulated length of stay and short-term mortality, close to reaching statistical 
significance (HR: 1.016, 95% CI: 0.999-1.032, P value=0.062), was identified in the general population 
study. 
A trend towards the accumulated length of stay and long-term mortality was identified in the general 
population study (HR: 1.009, 95% CI: 0.996-1.022, P value=0.170) and in the HFmrEF subgroup (HR: 
0.882, 95% CI: 0.740-1.052, P value=0.162). 
A trend towards the number of hospitalizations and long-term mortality close to reaching statistical 
significance (HR: 1.506, 95% CI: 0.994-2.283, P value=0.054) was found in the HFrEF subgroup. 
In the HFpEF subgroup both the length of stay per specific admission (HR: 1.063, 95% CI: 1.006-
1.123, P value=0.030) and the accumulated length of stay for all admissions (HR: 1.051, 95% CI: 1.008-
1.095, P value=0.019) were markers of worse long-term survival. 
8.2.2. ETIOLOGY 
The main causes of HF (i.e. ischemic cardiomyopathy, hypertensive cardiomyopathy and valvular 
cardiomyopathy) were studied but only the first showed an interesting result, since that in the subgroup of 
patients with HFrEF ischemic cardiomyopathy increased the risk of early readmission close to 5 times with 
an almost statistical significance (HR: 4.648, 95% CI: 0.892-24.225, P-value=0.068) and a trend towards 
ischemic cardiomyopathy and long-term mortality was also recognized (HR: 3.321, 95% CI: 0.789-13.977, 
P-value=0.102).  
8.2.3. LEFT VENTRICULAR EJECTION FRACTION 
We verified a trend towards short-term readmission and LVEF in the HFrEF subgroup (HR: 0.516, 95% CI: 
0.228-1.168, P-value=0.112). 
A trend towards short-term survival and LVEF was also patent in the HFrEF subgroup (HR: 0.274, 95% CI: 
0.053-1.422, P-value=0.123). 
As for long-term mortality, statistical significance was met in the HFrEF subgroup, as per increments of 
10% of LVEF a risk reduction of 65.2% was found (HR: 0.348, 95% CI: 0.135-0.899, P-value=0.029).  
8.2.4. REDUCED RIGHT VENTRICULAR FUNCTION 
We were able to identify a trend towards decreased TAPSE and long-term mortality (P-value=0.092). The 
mean TAPSE of the group of deceased patients was 17 mm. 
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A trend towards elevated PASP [median value in the group of patients who died of 45.00 (30.60-54.34 
mmHg)] and long-term mortality was found as well (P-value=0.086). 
Using descriptive analyses, we acknowledged that the absence of inferior vena cava inspiratory collapse 
was far more frequent in the group that died during the first 90 days post-discharge (33.3%) than in the 
survivor group (9.4%). The difference between the two groups was significant (P-value=0.015). 
Regarding long-term mortality, the absence of inferior vena cava inspiratory collapse was observed in 
only 2.6% of the patients who survived compared to 30.8% of those who died during follow-up, with an also 
significant difference between groups (P-value<0.001).  
8.2.5. OTHER ECHOCARDIOGRAPHIC FINDINGS 
In our study LV end-diastolic volume was a predictor of short-term mortality (P-value=0.027). 
The median LV end-diastolic volume value for the patients that survived was 56.87 (36.37-82.88) cm
3 
whereas in the subset of patients who died before 90 days post-discharge the median value was 105.40 
(85.25-150.00) cm
3
.  
 
Long- term mortality was also predicted by LV end-diastolic volume (P-value=0.023). 
The median value for the patients that survived was 44.57 (34.79-76.44) cm
3 
while in the subset of patients 
who died through follow-up the median value was 84.07 (58.83-151.00) cm
3
.  
8.2.6. REFRACTORY SIGNS OF CONGESTION 
According to descriptive analyses, hepatomegaly was observed in only 1.9% of the patients that 
survived the first 90 days post-discharge versus 25% of those who deceased in that period.  
The difference between the two groups was statistically significant (P-value=0.018), as represented in Figure 
2. 
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Figure 2 - Baseline comparison of subjects by short-term mortality status: Hepatomegaly 
 
As for long-term mortality, hepatomegaly was observed in 15.4% of the patients that died, but 
unremarkable in the survivors; again statistical power was achieved (P-value=0.022).  
 
8.2.7. THERAPEUTICS 
A trend towards angiotensin-converting-enzyme (ACE) inhibitor use and improved long-term survival was 
perceived in the general population study and in the HFmrEF subgroup (HR: 0.277, 95% CI: 0.050-1.535, P-
value= 0.142).  
8.2.8. MODIFIABLE CARDIOVASCULAR RISK FACTORS- THE METABOLIC 
SYNDROME 
Concerning cardiovascular (CV) risk factors, a trend towards dyslipidemia and risk of early readmission was 
identified in the subset of patients with HFrEF subgroup (HR: 3.952, 95% CI: 0.761-20.524, P-value= 
0.102). 
We detected a trend towards long-term mortality and dyslipidemia in the HFmrEF group HR: 5.346, 95% 
CI: 0.622-45.919, P-value=0.127). 
A trend towards long-term mortality and diabetes, limited to the ischemic cardiomyopathy subgroup, was 
perceived (HR: 1.909, 95% CI: 0.738-4.940, P-value=0.183). 
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A trend towards obesity and improved long-term survival was observed (HR: 0.436, 95% CI: 0.150-1.266, 
P-value=0.127) and a trend towards better short-term survival and higher BMI was identified in the HFpEF 
group (HR: 0.784, 95% CI: 0.570-1.077, P-value=0.133). 
We verified a trend towards the number of metabolic comorbidities and short-term readmission in the 
general population study (HR: 1.293, 95% CI: 0.908-1.842, P-value=0.154) and in the HFpEF group (HR: 
1.456, 95% CI: 0.826-2.564, P-value=0.194). 
We acknowledged a trend towards the number of metabolic comorbidities and short-term mortality in the 
HFrEF subset of patients (HR: 0.471, 95% CI: 0.165-1.346, P-value=0.160). 
8.2.9. OTHER RISK FACTORS 
8.2.9.1. Blood Pressure  
The mean systolic blood pressure of the patients that survived the first 90 days post-discharge was 147 ± 
30.0 mmHg versus 125 ±24.7 mmHg in the decedents. 
Univariate Cox regression revealed that, in general population study, the hazard of short-term mortality 
for patients with systolic blood pressure <100 mmHg was 5.3 times higher than that for patients with 
systolic blood pressure ≥ 100 mmHg (HR=5.330, 95% CI: 1.407-20.193, P-value=0.014). 
Figure 3 describes the Kaplan Meier short-term mortality curve for systolic blood pressure <100 mmHg. 
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Figure 3 - Short-term mortality - Kaplan Meier: Systolic blood pressure <100 mmHg 
 
As shown in Figure 4, the mean systolic blood pressure was significantly lower in the long-term mortality 
group than in the patients who survived (mean 149 ± 30.9 mmHg in the survivors versus 134 ± 27.2 mmHg 
in the deceased).  
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Figure 4 - Baseline comparison of subjects by long-term mortality status: Systolic blood pressure 
 
Comparatively to short-term mortality, for the referred value of systolic blood pressure (i.e. <100 
mmHg) the risk declined to 3.6 times (HR: 3.629, 95% CI: 1.239-10.631, P-value=0.019).  
Subgroup discrimination evidenced that long-term mortality hazard rose up to 6.3 times in the HFrEF 
subgroup (HR: 6.303, 95% CI: 1.224-32.452, P-value=0.028). 
Regarding diastolic blood pressure, Figure 5 depicts that the mean diastolic blood pressure was significantly 
lower (P-value=0.014) in the patients who died precociously compared to those who survived the early post-
discharge period (mean 80 ± 19.9 mmHg in the survivors versus 69 ± 10.6 mmHg in the decedents). 
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Figure 5 - Baseline comparison of subjects by short-term mortality status: Diastolic blood pressure 
 
The univariate Cox proportional hazard model estimated an increased risk of 11.1 times for short-term 
mortality in the HFrEF patients with diastolic blood pressure <60 mmHg (HR: 11.116, 95% CI: 1.000-
123.564, P-value=0.05). 
During follow-up the hazard declined to 8.5 times in the mentioned subgroup (HR: 8.462, 95% CI: 1.662-
43.096, P-value=0.010).  
 
8.2.9.2. Renal Function 
Chronic kidney disease was an important clinical prior regarding short-term mortality, being present 
in 45.3% of the survivors versus 83.3% of the decedents (P-value=0.024), as illustrated in Figure 6. 
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Figure 6 - Baseline comparison of subjects by short-term mortality status: Chronic kidney disease 
 
Regarding short-term readmission, median baseline urea in the non-early readmitted group was 44 (33-
62) mg/dL versus 70 (44-84) mg/dL in the early readmitted group; and admission urea was 51 mg/dL (36-
76) versus 92 (48-128) mg/dL for the referred groups, respectively. 
As for short-term survival, median baseline urea in the patients who survived the first 90 days post-
discharge was 44 (34-67) mg/dL versus 73 (66-89) mg/dL in those who died in that period; median 
admission urea was 54 (35-80) mg/dL versus 104 (74-143) mg/dL for the same groups, respectively. 
Minding long-term survival, median baseline urea was 44 (35-64) mg/dL in the survivors versus 70 (41-
84) mg/dL in those who died during follow-up; whereas median admission urea was 49 (34-74) mg/dL in 
the survivors versus 83 (50-124) mg/dL in those who died along follow-up.  
Median baseline creatinine in the non-early readmitted group was 1.0 mg/dL (0.8-1.2) versus 1.3 mg/dL 
(1.0-1.5) in the early readmitted group; while admission creatinine was 1.3 mg/dL (1.0-1.6) versus 1.6 
mg/dL (1.1-2.3) for the mentioned groups, respectively. 
Considering early mortality, median baseline creatinine in the patients who survived the first 90 days 
post-discharge was 1.0 (0.8-1.3) mg/dL versus 1.4 (1.2-1.5) mg/dL in those who died in that period; median 
admission creatinine was 1.2 (0.9-1.7) mg/dL versus 2.4 (1.6-2.7) mg/dL for the given subset of patients 
(Figure 7). 
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Figure 7 - Baseline comparison of subjects by short-term mortality status: Admission creatinine 
 
In what matters to long-term mortality, median baseline creatinine in the patients who survived was 1.0 
(0.8-1.3) mg/dL versus 1.2 (0.9-1.5) mg/dL in the group that died; while median admission creatinine was 
1.2 (1.0-1.5) mg/dL in the survivors versus 1.7 (1.3-2.6) mg/dL in those who died through follow-up. 
Referring to early readmission, median baseline GFR in the non-early readmitted group was 65.8 mL/min 
(48.1-83.3) versus 49.3 mL/min (41.1-74.7) mL/min in the early readmitted group; a median admission 
GFR of 56.5 mL/min (35.6-69.1) versus 36.5 mL/min (23.4-54.5) was found in the considered groups. 
Addressing short-term mortality, median baseline GFR in the early death group was 67.8 (47.3-83.5) 
mL/min versus 44.3 (35.6-50.5) in the group that died; while a median admission GFR of 56.5 (36.0-71.5) 
mL/min versus 23.4 (18.9-34.4) mL/min was observed in the two groups, respectively. 
Descriptive analysis showcased a median baseline GFR of 68.6 (47.3-84.4) mL/min in the survivors versus 
50.9 (41.8-74.5) mL/min in those who died throughout follow-up. 
The same statistical method demonstrated a median admission GFR of 56.5 (35.0-72.4) mL/min in the 
survivors versus 39.0 (20.0-57.6) mL/min in those who died along follow-up. 
The hazard for short-term rehospitalization increased 9.8% per 5 mg/dL increment of baseline urea (HR: 
1.098, 95% CI: 1.022-1.179, P-value=0.01).  
The risk for short-term rehospitalization augmented 4.8% per 5 mg/dL increment of admission urea (HR: 
1.048, 95% CI: 1.013-1.084, P-value=0.006). 
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An association between elevated baseline creatinine and early readmission was noticed (HR: 1.111, 95% CI: 
1.004-1.229, P-value=0.041), the risk augmented 11.1% per 0.1 mg/dL increment of creatinine. 
In relation to admission creatinine, the risk for early readmission augmented 4.7% per 0.1 mg/dL increment 
of creatinine (HR: 1.047, 95% CI: 1.005-1.092, P-value=0.027).  
Early readmission hazard increased 3.5 times with admission GFR <30 mL/min (HR: 3.535, 95% CI: 1.467-
8.518, P-value=0.005). 
With reference to short-term mortality the results were also interesting as both baseline and admission urea 
were significant risk predictors (HR: 1.145, 95% CI: 1.032-1.270, P-value=0.010, determining a 14.5% 
additional risk per increments of 5 mg/dL and HR: 1.076, 95% CI: 1.021-1.135, P-value=0.006, implicating 
a 7.6% increased risk per increments of 5 mg/dL, respectively).  
As for admission creatinine for each 0.1 mg/dL increment the risk for short-term mortality augmented 
12.7% (HR: 1.127, 95% CI: 1.055-1.204, P-value<0.001), for the same amount of increase for baseline 
creatinine the risk augmented 15.7% (HR: 1.157, 95% CI: 1.009-1.328, P value=0.037).  
Hazard analysis by subgroup of HF showed that for short-term mortality, focusing on HFrEF patients, the 
risk augmented 15.1% per 0.1 mg/dL increment of hospitalization creatinine (HR: 1.151, 95% CI: 1.010-
1.311, P- value=0.034). 
It is important to stress that admission GFR <30 ml/min increased the likelihood of early death 9.8 times in 
the entire population study (HR: 9.791, 95% CI: 2.855-33.580, P-value<0.001) and rose the risk up to 14.8 
times in the HFrEF subgroup (HR: 14.783, 95% CI: 1.267-172.493, P-value=0.032).  
On the subject of long-term mortality, admission urea elevated the hazard 5.6% per increments of 5 mg/dL 
(HR: 1.056, 95% CI: 1.019-1.094, P-value=0.003) in the total population study.  
In the HFrEF subgroup long-term mortality risk increased 10.5 % per increments of 5 mg/dL of admission 
urea (HR: 1.105, 95% CI: 1.037-1.177, P value=0.002) and 13.2% per increments of 5 mg/dL of baseline 
urea (HR: 1.132, 95% CI: 1.004-1.276, P value=0.042). 
With regard to long-term mortality admission creatinine worsened the outcome 10.4% per increments of 0.1 
mg/dL (HR: 1.104, 95% CI: 1.054-1.156, P- value<0.001) in the general population study, whereas in the 
subgroup of HFpEF the risk for this end-point was inferior, as per increments of 0.1 mg/dL of admission 
creatinine the risk raised only 8% (HR: 1.080, 95% CI: 1.007-1.159, P-value=0.032).  
Interestingly, in the HFrEF subgroup long-term mortality risk was greatest, since it increased 14.8% per 
increments of 0.1 mg/dL of admission creatinine (HR: 1.148, 95% CI: 1.051-1.253, P-value=0.002). 
Higher admission GFR decreased long-term mortality hazard around 20% per increments of 10 mL/min 
(HR: 0.788, 95% CI: 0.649-0.957, P-value=0.016) in the global population study. As for the HFrEF 
subgroup long-term mortality risk diminished 41% per increments of 10 mL/min of admission GFR (HR: 
0.590, 95% CI: 0.365-0.953, P-value=0.031). 
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Admission GFR <30 ml/min increased the hazard 3.9 times (HR: 3.906, 95% CI: 1.7208.871, P- 
value=0.001), while for admission GFR <15 ml/min the risk ascended to 6.1 times (HR: 6.087, 95% CI: 
1.403-26.402, P-value=0.016) in the overall population study.  
Minding the subgroup of HFpEF, long-term mortality correlated with admission GFR <30 ml/min (HR: 
3.640, 95% CI: 1.073-12.351, P-value=0.038) and in the HFrEF subgroup for admission GFR <30 mL/min 
this outcome risk augmented 13 times (HR: 13.387, 95% CI: 2.356-76.075, P value=0.003). 
Cardiorenal syndrome was present in 63.6% of the early readmitted patients, compared to 48.8% in the 
group not rehospitalized, notwithstanding statistical significance was not observed.
 
Descriptive analysis showed a prevalence of cardiorenal syndrome twice as superior in the short-term 
mortality group compared to those who survived (91.7% versus 45.3%, respectively, P-value=0.004). 
The Kaplan Meier short-term mortality curve for cardiorenal syndrome is illustrated ahead (Figure 8). 
 
 
Figure 8 - Short-term mortality - Kaplan Meier: Cardiorenal syndrome 
 
Descriptive analysis comparison revealed a 73.1% prevalence of cardiorenal syndrome in the long-term 
mortality group versus 41% in the survivors (P-value=0.011). 
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The presence of cardiorenal syndrome increased long-term mortality risk around 2.6 times in the 
global population study (HR: 2.582, CI: 1.120-5.950, P-value=0.026), achieving a 73.1% prevalence in the 
decedents and 41% in the survivors.  
As anticipated, long-term mortality hazard was superior in the HFrEF subgroup (HR: 8.567, 95% CI: 1.034-
70.981, P-value=0.046). 
 
8.2.9.3. Atrial Fibrillation  
In our study no connection was acknowledged between atrial fibrillation (AF) and the proposed outcomes. 
8.2.9.4. Bundle Branch Block  
Left bundle branch block (LBBB) determined a short-term mortality risk 3.4 times superior (HR: 
3.444, 95% CI: 1.051-11.293, P-value=0.041). It was present in 41.7% of the patients that died early, while 
it was present in only 17% of those that survived. 
The Kaplan Meier short-term mortality curve for LBBB is represented in Figure 9. 
 
Figure 9 - Short-term mortality - Kaplan Meier: LBBB 
REFERENCE 
Mário Barbosa     Página | 35  
 
Apropos of long-term survival, HFrEF patients with LBBB showed a HR of 4.1 (HR: 4.140, 95% CI: 
1.021-16.790, P-value=0.047).  
Descriptive analysis identified that only 4.7% of the non-early readmitted patients presented right bundle 
branch block (RBBB) versus 13.6% in the early readmitted patients (P-value=0.049). 
8.2.9.5. Hyponatremia  
Univariate Cox regression analysis found that, in HFmrEF patients with sodium <137 meq/L, the risk of 
early readmission was around 10 times greater. This association marginally missed statistical significance 
(P-value=0.053). 
8.2.9.6. Free Thyroxine 
Survival analysis showed a trend towards higher free thyroxine (FT4) levels and decreased early readmission 
risk in the HFmrEF subgroup (HR: 0.003, 95% CI: 0.000 -13.314, P-value=0.176). 
The mentioned statistical method identified a trend towards greater FT4 serum values and better short-term 
mortality rates in the HFrEF subgroup (HR: 0.008, 95% CI: 0.000 -2.939, P-value=0.108). 
Regarding long-term mortality, a trend towards higher FT4 serum values and lower risk, close to reaching 
statistical impact (HR: 0.210, 95% CI: 0.042-1.050, P-value=0.057), was acknowledged in the general 
population study, while statistical significance was met in the HFrEF subgroup (HR: 0.003, 95% CI: 
0.000-0.411, P-value=0.020).  
 
8.2.9.7. Anemia and Iron Deficiency 
The mean hemoglobin value for the non-early readmitted patients was 12.1 g/dL ± 1.8 versus 10.9 ± 1.8 
g/dL in the early readmitted group (Figure 10). Such difference between groups was statistically significant 
(P-value=0.012). 
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Figure 10 - Baseline comparison of subjects by early rehospitalization status: Hemoglobin 
 
After survival analysis, anemia (defined as hemoglobin <12 g/dL) tripled the risk for short-term 
readmission (HR: 3.200, 95% CI: 1.249-8.196, P-value=0.015) and with the delineation of gender 
thresholds, (i.e. females <12 g/dL and males <13 g/dL) a little increase of the risk was observed (HR: 
3.809, 95% CI: 1.287-11.275, P-value=0.016). 
Subgroup analysis demonstrated a greater short-term readmission risk for the HFrEF group for values of 
hemoglobin <12 g/dL (HR: 5.425, 95% CI: 1.006-29.251, P-value=0.049). Once again, gender related 
thresholds revealed an increase of the risk (HR: 9.183, 95% CI: 1.083-77.878, P-value=0.042). 
Respecting long-term mortality, in the HFrEF subgroup, anemia (defined as hemoglobin <12 g/dL) 
increased the risk up to 6.9 times (HR: 6.868, 95% CI: 1.337-35.278, P-value=0.021). Sex thresholds, as 
described above, further increased the risk (HR: 11.144, 95% CI: 1.349-92.069, P-value=0.025). 
Descriptive analysis revealed a median serum ferritin of 185.7 (64.0-374.2) ng/mL in the subset of patients 
that survived the first 90 days post-discharge versus 64.7 (38.2 - 90.8) ng/mL in the group that died in that 
length of time.  
Besides, applying hazard evaluation, serum ferritin <100 ng/mL determined a 7.2 increased risk of 
short-term mortality (HR: 7.220, 95% CI: 1.497-34.809, P-value=0.014). 
Figure 11 represents the Kaplan Meier short-term mortality curve for serum ferritin <100 ng/mL. 
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Figure 11 - Short-term mortality - Kaplan Meier: Serum ferritin <100 ng/mL 
In the HFrEF subgroup elevated serum iron was a protective factor as per each increase of 10 ug/dL 
short-term mortality risk decreased 65.8% (HR: 0.342, 95% CI: 0.119-0.982, P-value=0.046).  
In HFpEF patients a trend towards increased total iron binding capacity and early rehospitalization was 
detected (HR: 0.913, 95% CI: 0.822-1.014, P-value=0.090). 
8.2.9.8. Red Cell Distribution Width 
Figure 12 demonstrates that the median red cell distribution width (RDW) in the non-early readmitted 
subgroup was 14.8 (13.8-15.4) % compared to 16.1 (14.5-17.6) % in the early readmitted subgroup (P-
value=0.009).     
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Figure 12 - Baseline comparison of subjects by early rehospitalization status: RDW 
 
Further hazard analysis demonstrated that RDW was a predictor of early readmission (HR: 1.350, 95% 
CI: 1.155-1.577, P- value<0.001). 
As expected, in the subset of patients with HFpEF the early readmission hazard was inferior to that of the 
general population (HR: 1.301, 95% CI: 1.070-1.581, P value=0.008). 
Moreover, RDW was, as well, a predictor of early and long-term mortality. 
Median RDW in the patients that survived the first 90 days post-discharge was 14.9 (13.8-15.7) % versus 
17.0 (14.9-17.7) % in the group that died precociously and median RDW in the patients that survived 
throughout follow-up was 14.8 (13.8-15.6) % versus 15.5 (14.8-17.2) % in the group that died. 
The risk decreased during follow-up (HR: 1.826, 95% CI: 1.288-2.588, P-value<0.001 for early mortality 
versus HR: 1.294, 95% CI: 1.098-1.525, P value=0.002 for long-term mortality). 
In the particular case of the HFrEF subgroup, once more, long-term mortality risk was superior to overall 
populations’ (HR: 1.480, 95% CI: 1.098-1.995, P value=0.01). 
8.2.9.9. Erythropoietin 
A trend towards short-term readmission and elevated erythropoietin values was recognized in both total 
population study (HR: 1.064, 95% CI: 0.994-1.140, P-value=0.074) and in HFrEF patients (HR: 1.084, 95% 
CI: 0.992-1.185, P-value= 0.074). 
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According to descriptive analysis, the median EPO value in the group of patients that survived the first 90 
days post-discharge was 14.12 (9.56-20.18) mU/mL compared to 33.04 (16.30-58.26) mU/mL in the group 
that died early.  
Moreover, per increments of 10 mU/mL the risk for short-term mortality increased 37.7% (HR: 1.377, 
95% CI: 1.043-1.816, P-value=0.024). 
The median erythropoietin value in the group of patients that survived through follow-up was 11.97 (7.99-
16.44) mU/mL versus 19.46 (15.15-50.98) mU/mL in the group that died (P-value=0.002). Figure 13 
represents these results. 
 
   
Figure 13 - Baseline comparison of subjects by long-term mortality status: EPO 
 
Mortality risk reduced along follow-up given that for long-term mortality the risk increased 28.5% per 
increments of 10 mU/mL (HR: 1.285, 95% CI: 1.105-1.494, P-value=0.001).  
Further analysis per subgroup of HF regarding long-term mortality, showed that in the HFrEF subgroup, the 
risk augmented 81.4% per increments of 10 mU/mL (HR: 1.814, 95% CI: 1.141-2.884, P-value=0.012) and 
a trend towards increased risk was noted in the HFpEF subgroup (HR: 1.295, 95% CI: 0.933-1.796, P-
value=0.122). 
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8.3. BIOMARKERS 
8.3.1. BRAIN NATRIURETIC PEPTIDES 
The plasma concentration of NT-proBNP was lower in the obese [median 7588 (2544-15815) ng/L for 
non-obese versus 1475 (918.5-5643) ng/L for the obese, P-value=0.006)]. 
Spearman's correlation showed an inversely proportional relation between NT-proBNP and LVEF 
(Coefficient: -0.365, P-value=0.004). 
The same statistical method evidenced an inverse correlation between NT-proBNP and baseline and 
admission GFR (Coefficient: -0.418, P-value<0.001 for baseline GFR and Coefficient: -0.438, P-
value<0.001 for admission GFR). 
The median admission NT-proBNP in the patients that survived the first 90 days post-discharge was 4993 
(1730-11260) ng/L versus 9302 (4104-24502) ng/L in the short-term mortality group. 
The hazard of short-term mortality increased 0.5% per increments of 100 ng/L of admission NT-
proBNP (HR: 1.005, 95% CI: 1.002-1.009, P-value=0.002) and with a cut-off value of 21336 ng/L the 
mortality risk was 10.5 times greater (HR: 10.524, 95% CI: 3.013-36.757, P-value<0.001).  
Descriptive analysis revealed that the long-term mortality group had significant (P-value=0.022) higher 
values of admission NT-proBNP compared to those who survived [median 9302 (3917-20452) ng/L in the 
group that died during follow-up versus 4340 (1278-8031) ng/L in the group that survived]. Such findings 
are expressed in Figure 14. 
 
Figure 14 - Baseline comparison of subjects by long-term mortality status: Admission NT-proBNP 
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Survival analysis exposed a risk for long-term mortality close to 5 times with admission determinations 
≥21336 ng/L (HR: 4.791, 95% CI: 1.885-12.178, P-value<0.001). 
Additional analysis documented that the hazard for long-term mortality increased 0.3% per increments 
of 100 ng/L of admission NT-proBNP (HR: 1.003, 95% CI: 1.001-1.006, P-value=0.013). 
Figure 15 portrays that there was a significant difference (P-value=0.045) in the median discharge values of 
NT-proBNP between the long-term mortality group and those that survived [median 4773 (1267-8424) 
ng/L in the group that died compared to 1524 (311-4432) ng/L for the survivors]. 
  
 
Figure 15 - Baseline comparison of subjects by long-term mortality status: Discharge NT-proBNP 
 
Univariate Cox regression showed that the risk increased 0.6% per increments of 100 ng/L of discharge 
NT-proBNP (HR: 1.006, 95% CI: 1.001-1.011, P-value=0.028). 
8.3.2. TROPONINS 
Descriptive analysis estimated that the difference between the median hsTnT of the long-term mortality 
group and those that survived [median 108 (54-209) ng/L for the decedents compared to 39 (27-58) ng/L for 
the survivors] was statistically significant (P-value= 0.023). 
Univariate Cox regression showcased that the long-term mortality probability increased 7.7% per 
increments of 10 ng/L of hsTnT (HR:  1.077, 95% CI: 1.007-1.151, P value=0.030). 
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We explored the combination of hsTnT and admission NT-proBNP and realized that for values of hsTnT 
≥52 ng/L and NT-proBNP ≥21336 ng/L the risk of early readmission increased 8.6 times (HR: 8.607, 
95% CI: 1.413-52.427, P-value=0.020).  
As for long-term mortality, values of hsTnT ≥52 ng/L aggravated the hazard close to 5 times (HR: 
4.942, 95% CI: 1.044-23.388, P value=0.044), which heightened to almost 6 times if NT-proBNP at 
admission ≥21336 ng/L was considered (HR: 5.827, 95% CI: 1.168-29.075, P value=0.032). 
Figure 16 displays the Kaplan Meier long-term mortality curve for values of hsTnT ≥52 ng/L. 
 
 
Figure 16 - Long-term mortality - Kaplan Meier: hsTnT ≥52 ng/L 
 
8.3.3. GALECTIN-3 
The Spearman’s correlation coefficient was used to determine the relationship between Gal-3 and GFR, 
recognizing an inversely proportional relation between Gal-3 levels and baseline GFR (Coefficient: -
0.537, P-value<0.001) and admission GFR (Coefficient: -0.549, P-value<0.001). 
In contrast, Spearman's correlation revealed that Gal-3 and NT-proBNP values were proportional 
(Coefficient: 0.383, P-value=0.009). 
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A trend towards elevated Gal-3 determinations and ischemic heart disease was observed (median Gal-3 
value for ischemic heart disease 11.4 (8.3 - 12.6) ng/mL versus 9.2 (6.6 - 11.0) ng/mL in the patients without 
ischemic heart disease (P-value=0.138). 
Further analysis showed an association between increased Gal-3 values and short-term 
rehospitalization.  
The median Gal-3 value for non-early readmitted patients was 9.44 (7.30-10.96) ng/mL compared to 12.02 
(11.41-12.62) ng/mL in the early readmitted patients, as shown in Figure 17. 
 
   
Figure 17 - Baseline comparison of subjects by early rehospitalization status: Gal-3 
 
The analysis of the hazard ratios indicated an increased risk of 5.5 times for Gal-3 ≥9.99 ng/mL (HR: 5.449, 
95% CI: 1.124-26.411, P-value=0.035), for Gal-3 ≥ 10.97 ng/mL the risk augmented 9.9 times (HR: 9.886, 
95% CI: 2.027-48.214, P-value= 0.005) and for Gal-3 ≥11.41 ng/mL the risk augmented 11.8 times (HR: 
11.762, 95% CI:  2.402-57.598, P-value=0.002).  
If we added values of admission NT-proBNP ≥21336 ng/L to those of Gal-3 ≥10.97 ng/mL the risk 
further increased up to 12 times (HR: 11.985, 95% CI: 1.962-73.218, P value=0.007). For the HFrEF 
group the later determinations of NT-proBNP and Gal-3 represented a slightly superior risk of short-term 
rehospitalization (HR: 13.198, 95% CI: 1.165-149.465, P value= 0.037). 
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Descriptive analysis regarding short-term survival established a median Gal-3 of 9.31 (7.01-11.01) ng/mL 
in the group of patients that did not die early versus 12.59 (11.25-13.00) ng/mL in the short-term mortality 
group. 
Complementary survival analysis identified a 13.7 times increased risk for values of Gal-3 ≥10.97 ng/mL 
(HR: 13.731, 95% CI:  1.650-114.276, P value=0.015).  
Figure 18 demonstrates the Kaplan Meier short-term mortality curve for values of Gal-3 ≥10.97 ng/mL. 
   
Figure 18 - Short-term mortality - Kaplan Meier: GAL3 ≥10.97 ng/mL 
  
The combination of Gal-3 ≥11.41 ng/mL and admission NT-proBNP ≥1800 ng/L represented an 
increased risk of short-term mortality 18.8 times greater (HR: 18.837, 95% CI: 2.193-161.811, P-
value=0.007). 
Relatively to long-term survival, the median Gal-3 value was 9.24 (6.80-10.37) ng/mL in the group that 
survived compared to 11.36 (9.99-12.59) ng/mL in the deceased. This difference between groups was 
significant (P-value=0.029). 
Supplementary univariate Cox proportional hazard model added that serum determinations of Gal-3 ≥9.9 
ng/mL increased long-term mortality 4.5 times (HR: 4.492, 95% CI: 1.594-12.656, P-value=0.004).  
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The long-term mortality Kaplan Meier curve for levels of Gal-3 ≥9.9 ng/mL is exemplified in Figure 19. 
 
Figure 19 - Long-term mortality - Kaplan Meier: GAL3 ≥9.99 ng/mL 
 
For determinations of Gal-3 ≥10.97 ng/mL added to determinations of admission NT-proBNP ≥21336 
ng/L the same outcome presented an incremented risk of 78 times (HR: 78.025, 95% CI: 7.592-801.926, 
P-value<0.001). 
Subgroup interpretation indicated that serum concentrations of Gal-3 ≥11.41 ng/mL increased long-term 
mortality 10.8 times for HFrEF patients (HR: 10.777, 95% CI: 1.181-98.303, P-value=0.035).  
For Gal-3 ≥10.97 ng/mL and a cut-off of admission NT-proBNP ≥1800 ng/mL the HR was 13.5 (HR: 
13.511, 95% CI: 1.415-129.012, P-value=0.024). 
8.3.4. PRO-ADM 
In our research a trend towards MR-proADM and NYHA functional class IV was perceived [MR-proADM 
median value of 4.2 (3.7 - 4.5) pg/mL for class IV patients compared to 3.2 (2.7 - 4.2) pg/mL in the class III 
group, P-value=0.081). 
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We point out that in the HFmrEF subgroup a trend towards MR-proADM and early readmission was 
identified (HR: 13.209, 95% CI: 0.378-461.525, P-value=0.155). 
 
8.3.5. ST2 
Spearman's correlation indicated a significant negative relation between suppression of tumorigenicity 2 
soluble receptor (sST2) levels and baseline GFR (Coefficient: -0.418, P-value<0.001) and admission 
GFR (Coefficient: -0.438, P-value<0.001). 
A trend towards sST2 levels and male patients was also identified using the same statistical method [median 
value 37.5 (20.6 - 47.9) pg/mL for the males compared to 25.0 (14.3 - 36.1) pg/mL for the female patients, 
P-value= 0.089]. 
Likewise NT-proBNP, obese patients had lower amounts of sST2 [median 35.5 (22.3-46.4) pg/mL for 
non-obese versus 13.1 (10.1-23.4) pg/mL for the obese, P-value=0.001)]. 
We could not achieve a statistically significant link between sST2 and early mortality, when assessed 
isolatedly, although the subset of patients that survived had lower determinations that those who deceased 
[median 28.94 (14.40-42.52) pg/mL compared to 27.21 (23.81-54.50) pg/mL, respectively]. 
However the combination of sST2 ≥24.78 pg/mL and Gal-3 ≥9.99 ng/mL determined an 8 times 
increased risk for early mortality (HR: 8.108, 95% CI: 1.566-41.973, P-value=0.013). 
In the HFpEF subgroup, gathering serum determinations of sST2 ≥24.78 pg/mL and Gal-3 ≥10.97 ng/mL 
resulted in a HR of 19.3 (HR: 19.332, 95% CI: 1.657-225.567, P-value=0.018).  
Considering long-term mortality, elevated concentrations of sST2, were found to be a reliable predictor 
[median 22.33 (12.98-40.84) pg/mL in the group that survived compared to 35.47 (25.77-46.01) pg/mL in 
the group that died]. 
We recognized a risk for long-term mortality of 4.9 times for levels of sST2 ≥24.78 pg/mL (HR: 4.846, 
95% CI: 1.396-16.825, P-value=0.013).  
The long-term mortality Kaplan Meier curve for sST2 ≥24.78 pg/mL is depicted in Figure 20. 
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Figure 20 - Long-term mortality - Kaplan Meier: sST2 ≥24.78 pg/mL 
 
Remarkably for each increment of 10 pg/mL of sST2 the risk for long-term mortality elevated up to 
37% (HR: 1.372, 95% CI: 1.021-1.843, P-value=0.036). 
Curiously, if values of admission NT-proBNP ≥21336 ng/L were added to levels of sST2 ≥24.78 pg/mL 
the risk slightly augmented to 6 times (HR: 5.953, 95% CI: 1.683-21.055, P-value=0.006) and if, instead, 
values of Gal-3 ≥9.99 ng/mL were considered the risk increased roughly to the same extent (HR: 6.209, 
95% CI: 2.393-16.114, P-value<0.001). 
For the HFrEF subgroup the long-term mortality risk for the combined values of sST2 ≥24.78 pg/mL and 
values of Gal-3 ≥9.99 ng/mL was highest (HR: 15.782, 95% CI: 1.593-156.322, P-value=0.018) compared 
to the general population and the HFpEF subgroup (HR: 5.2, 95% CI: 1.223-22.187, P-value=0.026). 
For the HFpEF subgroup the long-term risk for the combined values of sST2 ≥24.78 pg/mL and admission 
NT-proBNP ≥1800 ng/L was 8.4 times higher (HR: 8.381, 95% CI: 1.003-70.037, P-value=0.05).  
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8.3.6. RECEIVER-OPERATOR CHARACTERISTIC (ROC) ANALYSIS 
As specified earlier, to analyze the prognosis capabilities of each biomarker individually and in combination, 
we need to have specific prognostic cut-offs for each of the biomarkers. 
Because there are no standardized cut-offs for these biomarkers, an assessment of the overall performance of 
each biomarker was performed using the multiclass AUCROC, as defined by Hand and Till, as a predictor 
of each of the events of interest. Taking into consideration the low number of subjects and samples, it was 
decided to consider as relevant predictors biomarkers which have an AUCROC above 0.7 and in which the 
95% confidence interval does not contain 0.5 (value for which the predictor makes random guesses). 
For the “Early Rehospitalization” outcome, the only biomarker with an acceptable AUCROC value 
was Galectin-3 (AUCROC: 0.74; CI95%: 0.55-0.92). For this biomarker, the optimal cut-off value 
(Youden Index) was 11.41 ng/mL with a high Negative Predictive Value (NPV: 0.93) indicating a good 
capability in predicting (93% probability) that no early rehospitalization events occur if the biomarker 
is below the cut-off. The Positive Predictive Value (PPV: 0.54) being able to predict the event with a 
probability of 54%. 
Regarding the remaining biomarkers, hsTnT had an almost relevant AUCROC (0.67) but with 95% 
confidence intervals too wide (0.44-0.89), probably due to the low number of samples available. 
For the “Early Death” outcome, there were two biomarkers with acceptable AUCROC values, 
Galectin-3 (AUCROC: 0.85; CI95%: 0.74-0.97) and NT-proBNP (AUCROC: 0.75; CI95%: 0.58-0.92) at 
admission to hospitalization.  
For Galectin-3, the optimal cut-off value (Youden Index) was 10.98 ng/mL with a perfect Negative 
Predictive Value (NPV: 1.0), indicating an excellent capability in predicting (100% probability) that no 
early death events occur if the biomarker is below the cut-off. Regarding the capability of predicting 
“Early Death” events, the biomarker has inferior capabilities (PPV: 0.44), but it is still relevant enough to 
take it into consideration, given the 44% probability of the event to occur. 
For NT-proBNP at admission to hospitalization, the optimal cut-off value (Youden Index) was 21336 
ng/L with a high Negative Predictive Value (NPV: 0.91). The Positive Predictive Value (PPV: 0.64) was 
inferior, being able to predict with 64% probability an event of early death. 
Regarding the remaining biomarkers, MR-proADM and NT-proBNP at the discharge of the hospitalization 
had almost relevant AUCROC values (0.65 and 0.68) but with 95% confidence intervals too wide (0.44-0.86 
and 0.40-0.97), once more probably due to the low number of samples available. 
For the “Long-term Death” outcome, we decided to consider two biomarkers with AUCROC slightly 
below 0.7, due to the fact that they have a significant behavior (95% confidence intervals are above 0.5). 
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For this outcome there were three biomarkers with acceptable AUROC values. Galectin-3 (AUCROC: 
0.69; CI95%: 0.52-0.86), ST2 (AUCROC: 0.69; CI95%: 0.53-0.85) and hsTnT (AUCROC: 0.77; CI95%: 
0.57-0.97).  
For Galectin-3, the optimal cut-off value (Youden Index) was 9.99 ng/mL with a Negative Predictive 
Value of 0.78 and Positive Predictive Value of 0.65. 
The ST2 biomarker has similar capabilities to Galectin-3, with an optimal cut-off value (Youden Index) of 
24.79 pg/mL with Negative Predictive Value of 0.83 and Positive Predictive Value of 0.60. 
The biomarker with best results for predicting long-term mortality was hsTnT. The optimal cut-off 
value (Youden Index) was 52 ng/L with a Negative Predictive Value of 0.85 and Positive Predictive 
Value of 0.62. 
Regarding the remaining biomarkers, NT-proBNP at admission to hospitalization was almost significant 
(AUCROC: 0.65; CI95%: 0.49-0.79). 
 
Characteristics Patients (n=65) Characteristics Patients (n=65) 
Age, mean (SD) 79.2 ± 10.8 LVEF, mean (SD) 50.38 ± 19.07 
Female Gender, n (%) 37 (56.9) 
Systolic Blood Pressure 
(Admission), median 
145.0 (121 - 163) 
Hypertension, n (%) 58 (89.2) 
Diastolic Blood 
Pressure (Admission), 
median 
77.0 (65 - 89) 
Type 2 Diabetes, n (%) 25 (38.5) GFR (Baseline), median 57.8 (43.8 - 82.2) 
Dyslipidemia, n (%) 41 (63.1) 
GFR (Admission), 
median 
47.9 (33.2 - 68.1) 
Obesity, n (%) 
 
17 (26.2) Urea (Baseline), median 47.0 (35 - 76) 
Atrial Fibrillation, n 
(%) 
28 (43.1) 
Urea (Admission), 
median 
64.0 (38 - 97) 
Family History of CVD, 
n (%) 
31 (47.7) 
Creatinine (Baseline), 
median 
1.0 (0.8 - 1.4) 
Tabagism, n (%) 21 (32.3) 
Creatinine (Admission), 
median 
1.3 (1.0 - 1.8) 
Chronic Kidney 
Disease, n (%) 
34 (52.3) 
Cardiorenal Syndrome, 
n (%) 
35 (53.8) 
Previous Acute 
Myocardial Infarction, 
n (%) 
27 (41.5) Hemoglobin, mean (SD) 11.7 ± 1.9 
Hypertensive 
Cardiomyopathy, n (%) 
44 (67.7) 
Red Blood Cell 
Distribution Width, 
median 
15.0 (13.8 - 16.2) 
Ischemic 
Cardiomyopathy, n (%) 
22 (33.8) Natremia, median 138.0 (136 - 140) 
Valvular 
Cardiomyopathy, n (%) 
56 (86.2) Serum Iron, median 40.1 (27.6 - 60.1) 
NYHA class III, n (%) 43 (66.2) Serum Ferritin, median 149.1 (52.3 - 350.9) 
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Transferrin Saturation, 
median 
14.0 (10 - 21) Anemia, n (%) 38 (58.5) 
Total Iron-Binding 
Capacity, mean (SD) 
281.5 ± 76.1 Iron Deficiency, n (%) 30 (46.2) 
Absolute Iron 
Deficiency, n (%) 
20 (30.1) 
Functional Iron 
Deficiency, n (%) 
10 (15.4) 
Anemia with Iron 
Deficiency, n (%) 
17 (26.2) 
Anemia without Iron 
Deficiency, n (%) 
15 (23.0) 
Iron Deficiency without 
Anemia, n (%) 
13 (20.0) 
Absolute Iron 
Deficiency without 
Anemia, n (%) 
6 (9.2) 
FT4, mean (SD) 1.19 ± 0.25 
Functional Iron 
Deficiency without 
Anemia, n (%) 
7 (10.8) 
NT-proBNP 
(Admission), median 
5701.0 (1867 - 11961) ACE Inhibitor, n (%) 43 (66.2) 
NT-proBNP 
(Discharge), median 
2837.0 (520 - 5085) Beta Blocker, n (%) 38 (58.5) 
hsTnT, median 51.0 (31 - 117) 
Mineralocorticoid 
Receptor Antagonists 
n (%) 
19 (29.2) 
Galectin-3, median 9.82 (7.94 -12.00) 
Angiotensin II Receptor 
Blocker, n (%) 
11 (16.9) 
ST2, median 27.22 (15.45-44.39) Loop Diuretic, n (%) 54 (83.1) 
Mid-Regional Pro-
Adrenomedullin, mean 
(SD) 
4.12 ± 0.95 Digoxin, n (%) 8 (12.3) 
Erythropoietin, median 14.89 (9.86 - 22.65) 
Left Ventricular 
Diastolic Diameter 
(LVDD), median 
53.0 (47 - 59) 
Pulmonary Artery 
Systolic Pressure 
(PSAP), median 
34.60 (25.94 - 50.05) 
Tricuspid Annulus 
Plane Systolic excursion 
(TAPSE), mean (SD) 
17.7 ± 4.0 
Left Ventricular 
Systolic Diameter 
(LVSD), median 
36.0 (19 - 78) 
Inferior Vena Cava 
Inspiratory Collapse 
(no), n (%) 
9 (13.8) 
Values are median (IQR), n (%), or mean ± SD. 
 
Table 2 - Baseline characteristics 
 
 
 
REFERENCE 
Mário Barbosa     Página | 51  
 
9. DISCUSSION 
This study confirmed the high early readmission rate of HF patients, as 33.8% of the population was 
rehospitalized within 90 days post-discharge. This readmission cypher is in accordance with the EPICA 
study which estimated a 20 to 30% readmission hazard for the referred period of time.
14,15 
The 30 day readmission rate was 15.4%, also in accordance with national data.
25 
The 30 day mortality rate was 10.8% similar to 11.75% found in the Multinational Observational Cohort on 
Acute Heart Failure (MOCA) study.
53 
We identified a 90 day mortality rate of 18.5%. Even though we excluded patients with active cancer, who 
have an elevated mortality, we registered a high percentage of death, slightly above some series,
8
 which 
reflects the severity of the clinical cases that we enrolled.
 
The year mortality was 36.9%, above the 30% registry of the British National Heart Failure Audit.
20
  
At the end of the follow-up 40% of the patients had deceased reflecting the severity of the HF syndrome. 
We believe that these findings corroborate the assumption that HF has a tremendous social and economic 
impact. 
Plenty clinical, hemodynamical, laboratorial and imagiological findings have been linked to the outcome of 
HF. 
Yet, given the complexity of the disease and multiple comorbidities that surround it, one should not rely on a 
solo indicator to estimate prognosis. 
Although some predictors correlate with HF outcome in a statistical and epidemiological basis, a single 
predictor may not be trustworthy to guide the therapy of an individual patient. 
The confluence of as many well established predictors of survival as possible seems to be the most accurate 
mean to assess the outcome.  
Some predictive models combine different prognosticators to estimate HF prognosis.
54, 55, 56 
However, these models are based on the analysis of a specific subset of patients and as new therapies 
emerge and guidelines are updated they become archaic, and first and foremost, clinical judgment is the 
essence of the art of making Medicine and shall never be replaced by a statistical model.  
Therefore such prognostic models should be used as a tool to help estimate more accurately the outcome of 
HF patients.  
The evolution of decompensated HF depends on multiple factors, namely its severity per se, its cause, the 
patient’s characteristics, therapeutics and follow-up. 
Despite its severity and chronicity, it is thought that more than half the readmissions for HF are 
preventable.
57 
The influence of the mentioned topics in the prognosis of the given population study will be scrutinized as 
follows.  
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9.1. DISEASE RELATED DETERMINANTS  
The diverging mortality rates among series reflect, essentially, different disease severity of the enrolled 
patients. 
Most of the data relative to survival come from systolic HF trials, since the information form diastolic HF is 
scarce. 
The length of stay for HF patients is estimated to be between four to five days in the mild cases and around 
nine days in the more severe presentations.
58, 59 
Relying on recent Portuguese Health System official data, HF as the primary diagnosis represents the second 
highest hospital burden, being responsible for 182 512 hospitalization days corresponding to 18 588 patients, 
with a mean hospital stay of 9.8 days and an in-hospital mortality of 12.5%.
23 
In our study the mean hospital stay was 8.3 days. 
We acknowledged a relation between the accumulated length of stay and early readmission, and subgroup 
analysis showed that the risk was highest for the HFrEF subgroup. 
A trend towards the accumulated length of stay and, both, short and long-term mortality was also identified. 
Subgroup analysis confirmed a consistent link between the accumulated length of stay and long-term 
mortality in the HFpEF. 
In the same subgroup the length of stay per specific HF hospitalization was a predictor of impaired long-
term survival. 
While in the HFrEF subgroup, a trend towards the length of stay for a given HF hospitalization and early 
readmission was verified. 
The number of hospitalizations correlated with short-term readmission in the overall population and in the 
HFmrEF subgroup and a trend towards greater risk in the HFpEF and the HFrEF subgroups was noted. 
A trend-towards the number of hospitalizations and long-term mortality, nearly reaching statistical 
significance, was verified in the HFrEF subgroup. 
Based on these findings, one can assume that the requirement for hospitalization is a relevant predictor of 
poor outcome as it reflects more severe disease and that patients hospitalized longer or repeatedly face a 
worse outcome. 
Our impression finds support in an analysis that studied patients with reduced or preserved LVEF from the 
Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program, 
which established an association between longer hospitalizations and nonfatal admissions with subsequent 
mortality rates.
60 
Reynolds et al., suggested that the length of stay could be a proxy for the severity of HF since this parameter 
was related with readmission and mortality within 30 days and 1 year independently of comorbidities and 
CV risk factors.
61
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Solomon and collaborators, verified an increase in mortality risk after each hospitalization, and the risk was 
highest after the first month of discharge decreasing progressively over time.
 60
 
The onset of HF has a major influence on the outcome. As per the EuroHeart Failure Survey II the overall 
mortality was 6.7%, ranging from 5.8% in CHF decompensated patients to 8.1% in de novo cases.
58 
In our study such comparison could not be made since all HF admissions were due to CHF decompensation 
given to the fact that acute coronary syndromes are the most frequent cause of de novo acute decompensated 
heart failure (ADHF)
2 
and ST-elevation acute coronary syndromes are routinely admitted to Cardiology ward 
in order to perform percutaneous transluminal coronary angioplasty and to recover, afterwards, in coronary 
care units, while non-ST-elevation acute coronary syndromes are often admitted to Internal Medicine ward.
 
9.1.1. ETIOLOGY 
It is consentaneously assumed that prognosis is inherently related to the underlying cause of HF. 
In the subgroup of patients suffering from HFrEF, a trend towards ischemic cardiomyopathy and early 
readmission and another trend towards long-term mortality were documented. 
Ischemic cardiomyopathy connotes with a worse prognosis than other common causes of HF. 
This fact has been documented for more than two decades ago.
62, 63 
In one study the etiology of cardiomyopathy was a relevant predictor of outcome, since the course of HF 
varied with its cause. For instance, ischemic cardiomyopathy patients had worse prognosis than those with 
hypertensive cardiomyopathy. Peripartum cardiomyopathy, a more benign and potentially reversible 
condition, had the best outcome.
64 
Interestingly a study performed in Brazil found that Chagas disease, a rare cause of HF in the western world, 
evolved with worse prognosis than other forms of HF.
65 
9.1.2. LEFT VENTRICULAR EJECTION FRACTION 
A, 2016, systematic review by Van Riet et al., suggested that the 'epidemic' of HF seems to be altering, since 
the prevalence of diastolic dysfunction is rising and currently superior to that of systolic dysfunction. The 
prevalence of the latter appears to have declined in the last century.
66 
In our study LVEF was a predictor of long-term mortality in the patients with HFrEF, as per increments of 
10% of LVEF a risk reduction of 65.2% was found. 
Moreover, a trend towards short-term readmission and LVEF and another trend towards short-term survival 
and LVEF were, also, present in the referred subgroup. 
Several major trials achieved similar conclusions. 
The Valsartan heart failure trial (Val-HeFT) revealed an association between LVEF and mortality.
67 
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The LVEF was inversely proportional to mortality, as patients with mean LVEF of 17% had a 23 month all-
cause mortality of 26% compared to those with an average LVEF of 35%, which had a 14% mortality for the 
same period of time.
 67 
This assumption was corroborated by the Studies of Left Ventricular Dysfunction (SOLVD) trials.
68 
A retrospective analysis from the CHARM trials suggested that compromised LVEF was a powerful 
independent predictor of mortality and HF hospitalization.
69  
Normally, HF due to systolic dysfunction becomes clinically evident when LVEF falls below the 35-40%.  
Nonetheless there is no accurate relation between clinical status and LVEF, as some patients with LVEF 
inferior to the above mentioned threshold are asymptomatic while others with higher LVEF refer symptoms.  
In our study the mean (SD) LVEF in the HFrEF was 26.91 ± 8.91 %. 
Gradman A et al., recognized that LVEF inferior to 20% is traditionally a marker of bad prognosis.
70 
Heart failure with borderline EF was first described, in 2013, in the ACA/AHA guidelines as the presence of 
HF symptoms and LVEF between 41% and 49%.
41 
In 2016, the ESC guidelines introduced a new concept for HF patients with LVEF between 40% and 49%, 
"heart failure with mid-range ejection fraction”.1 
This population is formed by patients with mild systolic dysfunction, but with characteristics of diastolic 
dysfunction.
1 
Therefore, patients are classified according to baseline LVEF into HFrEF (EF <40%), HFmrEF (EF between 
40-50%) and HFpEF (EF ≥50%).1 
In our study we stratified the population following the above mentioned criteria. 
Hsu et al., raise the question that HFmrEF could be a transition stage between HFpEF and HFrEF, rather 
than a distinct clinical entity. 
Albeit there are effective, guideline-directed therapies for HFrEF, therapies that objectively change the 
course of HFpEF and HFmrEF lack scientific support.
 71
 
9.1.3. NYHA FUNCTIONAL CLASS 
It has been proven that greater NYHA functional class patients evolve with worse prognosis since the late 
eighties.
72, 73 
The European Society of Cardiology Heart Failure Long-Term Registry confirmed that NYHA class III/IV 
status predicted mortality in all LVEF groups.
74 
Unfortunately, in our study we could not reach such conclusions most likely because of the limited 
participants enrolled. 
The fact that the selected population was in some way homogenous, given that only severe cases were 
included, impeding the comparison with mild and moderate cases, as conducted in other trials, could also 
contribute to this matter. 
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9.1.4. REDUCED RIGHT VENTRICULAR FUNCTION 
Although right ventricular function has a deleterious impact on HF prognosis, its assessment is often 
neglected, given the primordial role of the LV.  
Aronson and colleges associated pulmonary hypertension and right ventricular dysfunction, often seen in 
concomitance, to adverse outcome in patients with chronic heart failure.
75 
Tricuspid annulus plane systolic excursion <18 mm, which suggests right ventricular failure, has been 
connoted with poor CV outcome, namely death.
76 
In our study a trend towards TAPSE and long-term mortality was detected and the mean TAPSE of the 
group of the patients that died was 17 mm. 
A trend towards elevated PASP and long-term mortality was also verified and the median value in the group 
of patients who died was 45.00 (30.60-54.34) mmHg. 
The absence of inferior vena cava inspiratory collapse, a well-known parameter of right ventricular 
overload, was a powerful predictor of both short and long-term mortality. 
According to some authors the lack of inspiratory collapse of the inferior vena cava during the 
decompensation phase corresponded to a subgroup of patients with impaired long-term survival.
77 
The sum of these results leads us to believe that despite the undisputed role of LV function, the evaluation of 
the right ventricle can add relevant information to define HF prognosis. 
Furthermore clinical signs of right-sided HF, discussed ahead, correlated with worse prognosis. 
9.1.5. OTHER ECOGRAPHIC FINDINGS 
In our study LV end-diastolic volume was a predictor of, both, short and long- term mortality. 
The Val-HeFT investigators hold that LV dilation or an LV end-diastolic volume index >120 ml/m
2
, which 
are parameters that suggest LV systolic dysfunction,
67 
are determinants of worse outcome.
 
9.1.6. REFRACTORY SIGNS OF CONGESTION 
Refractory signs of congestion are indicative of lack of response to diuretics, a marker of reduced tissue 
perfusion and poorer outcome.
78 
Hepatomegaly, a clinical sign of congestive hepatopathy, which ultimately can progress to cardiac cirrhosis 
(hepatic fibrosis due to right-sided HF) was a predictor of short and long-term mortality. 
9.1.7. THERAPEUTICS 
Neurohumoral blockers represent a breakthrough in HF management as they have changed the course of the 
disease by effectively reducing mortality, readmission rates and ultimately warranting a better quality of life 
for CHF patients.
79 
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The SOLVD investigators realized that 90% of deaths in CHF patients are cardiovascular.
72 
The major causes of death in HF patients are progressive pump failure, which can be defined as continuous 
hemodynamic deterioration, due to cardiac malfunction, leading to death, and arrhythmic or sudden death, 
described as death within one hour of the onset of cardiovascular collapse in a previously stable patient. 
72, 73 
The milestone drugs in HF treatment, ACE inhibitors, beta blockers (BB) and mineralocorticoid receptor 
antagonist (MRA), have irrefutable impact on both mortality and hospitalization, although through different 
mechanisms. 
While ACE inhibitors improve cardiovascular burden mainly by preventing progressive myocardial 
dysfunction,
72,73
 BBs
80
 and MRAs
81 
reduce both sudden cardiac death and death derived from progressive 
pump failure. 
Faith is deposited in the new drug valsartan/sacubitril, which reduced the composite endpoint of 
cardiovascular death or HF hospitalization significantly, by 20%, in symptomatic patients with HFrEF 
tolerating an adequate dose of either ACE inhibitor or angiotensin receptor blocker (ARB).
82 
Kfoury et al., found a beneficial relationship between adherence to treatment and one-year survival.
83 
The British National Heart Failure Audit confirmed that post-discharge mortality at one year correlated to 
administration of disease-modifying drugs for HFrEF.
20 
The greatest benefit was achieved in patients leaving hospital medicated with ACE inhibitors, ARBs, BBs 
and MRAs.
20
 
We were only capable of identifying a trend towards ACE inhibitor use and long-term mortality in the 
general population study and in the HFmrEF subgroup. 
Lack of adherence to treatment (lifestyle modification and drugs) is a major issue in chronic diseases, 
particularly in HF.
84 
Michalsen A et al. argue that it is the most frequent cause of readmission due to HF, being responsible for 
41% of the cases. The same series found that 12% of the readmitted patients where undertreated.
84 
Baretto and colleges concluded that considering that the main culprit of hospitalizations is inappropriate 
treatment, whether non-compliance or non-optimization, more assertive health care strategies combined to 
an effective treatment could result in an improvement of HF patients’ wellbeing and decrease hospital 
costs.
65 
Compliance to standard of care measures plays an essential role in post-discharge outcome.  
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9.2. HIGH RISK PATIENTS’ PROFILE 
9.2.1. NON MODIFIABLE CARDIOVASCULAR RISK FACTORS 
Concerning patient characteristics, advanced age and the male gender appear as risk factors for hospital 
readmission, in studies carried out in Europe
85
 and in the USA
31
. 
There is a consistent link between increased readmission rates with age, since older patients are prone to 
more severe clinical conditions and suffer from a larger range of comorbidities. As a matter of fact 
morbidities and functional impairment are pointed as risk factors for rehospitalization in the elder.
86 
The Framingham Heart Study has proven more than two decades ago that mortality is proportional to 
advancing age.
87 
Modern HF trials, namely a post-hoc analysis from the CHARM study, have also demonstrated a significant 
relation between advanced age and all-cause mortality, after adjusting for known predictors of CV outcome. 
The risk augmented gradually with age and peaked at older groups.
88 
Lately, the European Society of Cardiology Heart Failure Long-Term Registry verified that advanced age 
predicted mortality in all LVEF groups.
74  
In a Portuguese study revising all-cause readmissions the incidence of rehospitalization did not vary with 
age among adult patients, nevertheless older patients (≥ 65) had an increased mortality (18.2% vs.10.6% in 
the 45-64 year old interval).
28 
The present study was composed by a very uniform population in terms of age which prevented inferences. 
Nevertheless, a trend towards compromised short-term survival and age ≥ 90 years was noted in HFpEF. 
Albeit the comparison among distinct age groups did not show significant differences, the fact that in this 
aging population almost half of the patients died during follow-up, fundaments the impression that in CHF 
mortality is inherently related to advanced age. 
The variation of readmissions with gender can be explained by the fact that, when compared to women the 
same age, the males have more severe clinical issues and greater mortality.
85 
According to national data, in the particular case of HF, male patients show a greater risk of readmission.
28  
The Framingham Heart Study found that women have better prognosis than men. Median survival after HF 
diagnosis was 3.2 years for women and 1.7 years for men. After 5 years only 38% of female patients were 
alive and 75% of men had deceased.  
Curiously if only the subset of patients who survived the first 90 days were considered, survival rate rose up 
to 53% in women and 35% in men.
87
 
This finding supports our assumption that the first 90 days post-discharge are critical in HF management. 
The Cardiac Insufficiency Bisoprolol Study (CIBIS II) trial proved that regardless of BB treatment and 
baseline clinical profile, female gender is a significant independent predictor of survival in patients with 
CHF.
89 
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Another analysis from the CHARM program showed that women have better fatal and nonfatal 
cardiovascular outcome than men.
90 
 In our study 32.4% of women were readmitted preciously versus 35.7% of men.  
Short-term mortality was similar between genders (18.9% for the females versus 17.9% for the males) but 
men showed a greater percentage of long-term death (42.9% versus 37.8%). 
There is conflicting evidence whether race plays a role in HF outcome. 
According to post-hoc analysis from the SOLVD trial black patients presented with higher mortality 
91, 92 
while in a post-hoc analysis from the Digitalis Investigation Group (DIG) trial mortality rates were similar 
between blacks and caucasians.
93
 
In our study no difference in outcome regarding to race was observed, however one should be cautious to 
extrapolate such findings given that the participants were almost entirely caucasian. 
9.2.2. MODIFIABLE CARDIOVASCULAR RISK FACTORS - THE METABOLIC 
SYNDROME 
In 1988, Reaven described a triad of CV risk factors formed by arterial hypertension, diabetes and 
dyslipidemia, and designated it insulin resistance syndrome.
94 
In 1998, the WHO completed the constellation of CV risk factors by adding obesity and microalbuminuria, 
naming it metabolic syndrome.
95 
The progressive improvement in HF outcome is owed to the advance of the treatment of the disease (the 
continuous arrival of new drugs and devices and constant review of the guidelines), but also to concomitant 
improvement of the management of the underlying causes and cardiovascular risk factors. 
Considering that metabolic disorders are in the genesis of CV diseases, it is plain to see that it is crucial to 
control these modifiable risk factors, in order to abrogate the CV risk continuum. 
In our trial a trend towards the number of comorbidities and short-term readmission in the general 
population study and in the HFpEF group was identified. 
Furthermore, we acknowledged a trend towards the number of comorbidities and short-term mortality in the 
HFrEF subset of patients. 
Cardiovascular disease is responsible for 4 million deaths in Europe each year.
96 
Cardiovascular diseases represent the major cause of morbidity and mortality in the western world and are in 
crescendo in developing countries, and are also outlined as the main cause of hospital readmission. 
31 
The VALSIM study, a landmark study that addressed the metabolic syndrome´s impact in Portugal, 
recognized a 27.5% overall prevalence.
97 
Adding to this matter, according to national epidemiologic studies, 24% of the population smokes.
98  
In our study 32.3% of the population were active smokers or had a tabagism past. 
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Furthermore, Isabel do Carmo and colleges, acknowledged that Portugal registers one of fastest growing 
rates of overweight and obesity in Europe, affecting 53% of the population between 18-64 years of age.
99 
The PREVADIAB study documented an astonishing cipher of three million Portuguese suffering from 
diabetes or impaired glucose metabolism.
100 
We verified a 38.5% prevalence of diabetics in the enrolled population.
 
The PHYSA study revealed that 42.2% of the Portuguese adult population is hypertensive,
101
 in accordance 
with the 30-45% prevalence estimated in European registries
44
. 
Importantly, 74.9% of Portuguese hypertensive patients are treated and, only, 42.5% are controlled.  
The average daily consumption of salt is 10.7 g, way above the recommended 5.8 g.
101 
In our study a remarkable 89.2% of hypertensive patients
 
were identified.
 
This remarkable prevalence of arterial hypertension mimics the EPICA findings that arterial hypertension is 
the most frequent risk factor in HF patients.
14 
Concerning dyslipidemia, relying on WHO data, the prevalence of elevated total cholesterol was highest in 
Europe (54% for both sexes).
102 
The VALSIM study documented a 46.06% prevalence of dyslipidemia in Portugal.
97 
We found a 63.1% prevalence of dyslipidemia
 
in our study. 
Importantly, we recognized a trend towards dyslipidemia and risk of early readmission in the subset of 
patients with HFrEF. 
Besides, a trend towards long-term mortality and dyslipidemia was also identified in the HFmrEF group. 
From the exposed CV risks, diabetes stands out as a contributor to aggravate HF prognosis. 
Diabetes alone can induce myocardial strain resulting in both systolic and diastolic ventricular dysfunction, 
in the absence of other possible etiologies, the so called “diabetic cardiomyopathy”.103 
A retrospective analysis from the CHARM program, which reviewed the prognostic value of several 
variables, revealed that diabetes was an independent risk factor for all-cause mortality and HF admissions in 
patients with ischemic cardiomyopathy.
69 
Data from the SOLVD trials confirmed that among patients with HF, the diabetic had higher mortality rates 
and were significantly more expected to be admitted for HF (risk ratio 1.6).
104 
We found a trend towards long-term mortality and diabetes, limited to the ischemic cardiomyopathy 
subgroup, likewise the SOLVD trial that confirmed an increase in all-cause mortality linked to diabetes, 
also, restricted to patients with ischemic cardiomyopathy (adjusted relative risk 1.37 compared to 0.98 in 
patients with non-ischemic cardiomyopathy). In the presence of coronary disease, diabetes presented as an 
independent predictor of worse outcome and was third in order of significance, after age and LVEF.
105
 
It is thoroughly known that obesity is an independent risk factor for cardiovascular disease, nevertheless 
relying on data from The Acute Decompensated Heart Failure National Registry (ADHERE), obesity is not 
responsible itself for HF death.
106
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Horwich et al., in a large cohort of patients with advanced HF of multiple etiologies, realized that obesity 
was not linked to increased mortality and, surprisingly, could assure a more favorable prognosis.
107
 
The percentage of obesity in our population study was 26.2%. 
The CHARM investigators found that lower BMI was associated with a greater risk of cardiovascular death 
and non-cardiovascular death than BMI ranging from 30-34.9 kg/m
2
.
108 
A lower BMI was independently related with mortality in HFrEF and HFpEF patients in the European 
Society of Cardiology Heart Failure Long-Term Registry.
74 
In parallel with the described studies, in our investigation obesity was not a risk factor for worse CV 
outcome, better off, a trend towards improved long-term survival was perceived. 
A trend towards improved short-term survival and higher BMI was, as well, identified in the HFpEF 
subgroup. 
Underweight could be a consequence of more severe disease, namely cardiac cachexia which, notoriously, 
evolves with poor prognosis.  
9.2.3. OTHER RISK FACTORS 
The ADHERE Registry followed more than 65 000 patients from several hospitals throughout the USA.
59 
This study was able to establish a risk stratification of HF patients based on ordinary evaluation data.  
Urea levels >86 mg/dL, creatinine levels >2.75 mg/dL and systolic blood pressure <115 mmHg where 
consistent markers of poor outcome. 
According to this stratification low risk patients had a 2.2 % mortality percentage while the high risk group 
had a 20.9% mortality rate. 
9.2.3.1. Blood Pressure  
Low blood pressure plays a role in HF outcome as it is a clinical sign of lack of tissue perfusion and more 
severe disease. 
Decreased systolic, diastolic and mean blood pressure values correlate to reduced survival. 
A post-hoc analysis of the DIG trial established a trend towards increased mortality in patients with systolic 
blood pressure <100 mmHg and diastolic blood pressure <60 mmHg.
109 
In the SOLVD study, each 10 mmHg decrease in baseline mean arterial pressure was associated with a 14% 
increase in global and cardiovascular mortality.
110 
The European Society of Cardiology Heart Failure Long-Term Registry concluded that low systolic blood 
pressure was a predictor for mortality in HFrEF and HFmrEF patients.
74
 
Our results consubstantiate these milestone studies as systolic blood pressure was a prognosticator of short-
term mortality. Besides, systolic blood pressure <100 mmHg increased short-term mortality risk more than 5 
times. 
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In resemblance with the exposed data, we found a link between systolic blood pressure and long-term 
mortality. Comparatively to short-term mortality, the risk declined along follow-up. 
As anticipated, the HFrEF subgroup presented the highest hazard for long-term mortality. 
Regarding diastolic blood pressure it was also a predictor of short-term mortality and for values of diastolic 
blood pressure <60 mmHg the risk for short-term mortality increased 11.1 times in the HFrEF subgroup. 
Diastolic blood pressure <60 mmHg was, also, a maker of worse long-term survival in the HFrEF subgroup, 
and, again, the risk was inferior to that of early mortality. 
These results suggest that both short-term and long-term mortality risk related to low blood pressure is 
greatest in HFrEF patients.  
Remarkably, the risk seems to decline after the crucial 90 days post-discharge. 
9.2.3.2. Renal Function 
Renal dysfunction also represents impaired tissue perfusion. 
Major studies like the EuroHeart Failure Survey II and the ADHERE have established renal impairment as a 
marker of poor prognosis.
58, 59 
A systematic review stated that renal failure is a predictor of poor outcome since it implicates higher rates of 
mortality and hospitalization in patients with HF.
70 
Smaller trials have also been able to confirm this statement.
65 
The European Society of Cardiology Heart Failure Long-Term Registry verified that chronic kidney disease 
predicted mortality in all LVEF groups.
74
 
In our study the patients with impaired renal function evolved with a worse prognosis as several renal 
function parameters correlated consistently with precocious readmission and all-cause mortality. 
Based on our results one can infer that abnormal baseline values of urea and creatinine (which can represent 
CKD) correlated better with worse short-term readmission and short-term mortality prognostication than 
altered admission values (which could represent only acute kidney injury).  
Subgroup analysis, corroborated this assumption given that in the HFrEF subgroup long-term mortality risk 
was greater with elevated baseline urea (HR=1.132) than with elevated admission urea (HR=1.105). 
In what matters to long-term mortality the hazard was, plausibly, greater for admission GFR <15 ml/min 
than for GFR <30 ml/min. 
As expected, for admission GFR <30 ml/min the risk for long-term mortality was inferior in the subgroup of 
HFpEF (HR=3.640) comparing to that of the general population (HR=3.906) and the risk for this end-point 
was also inferior considering admission creatinine for the given groups (HR=1.080 versus HR=1.104, 
respectively). 
Subgroup analysis confirmed an expected worse outcome for short-term mortality in HFrEF patients, 
compared to general population study for similar increments of creatinine and for GFR <30 ml/min. 
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Coherently, long-term mortality risk was greatest, regarding admission creatinine and GFR <30 ml/min, in 
the HFrEF subgroup (HR=1.148 and HR=13.387, respectively). 
Remarkably, the HFrEF benefited more from the increase in admission GFR than general population, in 
what matters to long-term survival. This finding suggests that HFrEF is a vulnerable subgroup in which 
renal function is a determinant marker of prognosis. 
We believe that the fact that all the renal function parameters, customarily used in general practice, 
correlated consistently with the aimed end-points, adds valuable information concerning HF prognosis. 
Furthermore, CKD was an important clinical prior as it correlated with short-term mortality (present in 
45.3% of survivors versus 83.3% of the decedents) and cardiorenal syndrome was found to be a strong 
predictor of both short and long-term mortality. Once again, the long-term mortality hazard, related to 
cardiorenal syndrome was greatest in the HFrEF subgroup.  
9.2.3.3. Atrial fibrillation 
Atrial fibrillation and concomitant HF is very frequent.
111, 112   
In our population AF reached a remarkable prevalence of 43.1%.  
There is some controversy relative to its prognostic significance since some studies point it as an 
independent mortality risk predictor while others do not. 
A retrospective analysis of the SOLVD trials compared patients with AF to those in sinus rhythm, and 
concluded that AF, in patients with asymptomatic or symptomatic left ventricular systolic dysfunction is 
related with an increased risk for all-cause mortality.
112 
The authors presumed that AF is related with progressive left ventricular systolic dysfunction, implicating 
an increased risk for pump-failure death.
112 
A contemporary analysis of the Framingham cohort over 50 years, validated this presumption.
113 
Atrial fibrillation predicted mortality in HFpEF patients in the European Society of Cardiology Heart Failure 
Long-Term Registry.
74
 
However, likewise, the Veterans Affairs Vasodilator-Heart Failure Trial (V-HeFT I and II) investigators that 
defended that AF does not increase major morbidity or mortality in CHF,
111 
in our study no connection was 
acknowledged between AF and CV outcomes. 
9.2.3.4. Bundle Branch Block  
Left Bundle Branch Block is a common ECG finding in HF, present in about 25% of the patients as 
specified by some series.
114, 115 
In our study the percentage of LBBB (21.5%) was close to the available data. 
Although it has been reported that QRS prolongation  ≥120 msec, in HF patients, is associated with 
increased all-cause mortality
114, 115, 116
 and even sudden death
114
, there is conflicting data regarding its direct 
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impact on mortality, since some found it to be an independent risk factor for mortality
114
 while others did 
not
115
. 
Such divergence raises the question whether LBBB is just a marker of worse outcome or a consistent and 
direct cause of mortality. 
In our study LBBB was a marker of short-term mortality risk in the overall population study. 
Regarding long-term survival, LBBB was also a predictor of worse outcome in the HFrEF subgroup. 
Ventricular dyssynchrony as an effect of anomalous conduction could justify the adverse outcome.
114 
According to Mueller et al., RBBB is a powerful predictor of mortality in patients with ADHF, and so 
prompt recognition of this high-risk group could help to offer tailored treatment in order to improve the 
prognosis.
117 
We were able to detect a link between RBBB and early HF readmission in the general population study. 
Pellicori et al., also document a worse outcome in HF patients with RBBB. 
According to these authors patients with QRS ≥120 msec with RBBB morphology frequently have more 
severe bi-ventricular dysfunction.
118
 
9.2.3.5. Hyponatremia  
Hyponatremia results from a series of physiologic compensation mechanisms to balance the low output state 
patent in HF. 
Hyponatremia is frequent in HF patients and is a recognized predictor of short-term outcomes in HF.
119 
Otherwise unexplained hyponatremia was associated to poor prognosis in a study that enrolled patients with 
severe HF, as patients with sodium <137 meq/L had less than half the median survival (164 Vs 373 days).
120 
An observational study from the Duke Databank for Cardiovascular Diseases evidenced that in HF patients 
with LV systolic dysfunction hyponatremia was independently linked to increased risk of all-cause mortality 
and cardiovascular mortality/rehospitalization.
119
  
The cut-off of sodium <137 meq/L, increased early readmission hazard around 10 times in the HFmrEF 
subgroup, although, statistical significance was marginally missed (P-value=0.053). 
9.2.3.6. Free Thyroxine 
Hypothyroidism, defined as elevated serum values of thyroid stimulating hormone (TSH), associated to 
decreased levels of FT4 or free triiodothyronine (FT3) has been pointed as a risk factor of HF.  
Thyroid hormones play an important role in cardiovascular homeostasis, as FT4 and FT3 favor inotropism 
and chronotropism, and also mediate diastolic function and systemic vascular resistance.
121 
Nevertheless, the mechanism by which hypothyroidism aggravates HF outcome needs clarification. 
We recognized that HFmrEF patients with higher FT4 levels showed a decreased early readmission rate. 
REFERENCE 
Mário Barbosa     Página | 64  
 
Subgroup analysis also identified that HFrEF patients with greater FT4 concentrations evolved with a better 
short-term survival. 
Concerning long-term mortality, FT4 also had a protective role as in the general population study and in the 
HFrEF subgroup, those with higher values had a better prognosis. 
Our results find fundament in a meta-analysis that included 13 articles, which acknowledged that these 
impaired thyroid hormones determined an increased risk of all-cause mortality, as well as hospitalization, in 
patients with HF.
122 
 
We believe that the recognition and treatment of risk factors that influence HF outcome, namely 
hypothyroidism, beyond HF specific therapy, may further contribute to ameliorate HF prognosis.  
9.2.3.7. Anemia and Iron Deficiency 
Mild anemia is a common condition in patients suffering from chronic diseases, of which HF is no 
exception.
123 
Moreover, a 2017 Portuguese study documented that anemia and iron deficiency are highly prevalent in 
older Portuguese adults, particularly amongst those over 80 years of age, affecting 31.4% and 42.8%, 
respectively, of the referred age group.
124 
Another 2017 Portuguese study addressing this topic, the PRO-IRON study, acknowledged that anemia and 
iron deficiency are extremely frequent conditions in patients admitted to Internal Medicine ward, and 
correlate with in-hospital mortality.
125
  
We were able to confirm such high rates as 58.5% of the population studied had anemia and 46.2% had iron 
insufficiency. 
In the particular case of ADHF, according to the available data, the prevalence of iron deficiency ranges 
from 50% to 80%. 
126, 127, 128, 129
 
Importantly, iron depletion in the setting of ADHF is predominantly absolute,
128, 129  
as observed in our 
study.
 
Customarily, anemia results from depleted iron supplies and/or impaired transportation.
130
 
Anemia complicating congestive HF is multifactorial, resulting from the combined effect of hemodilution 
compromised glomerular filtration rate, iron deficiency, inflammation.
130
 
Nonetheless, HF, per se, promoting inflammatory response through cytokine production, is sustained by 
Silverberg and collaborators, as a potential mean of damaging the bone marrow and therefore provoking 
anemia.
131 
It has, also, been postulated that HF patients may develop iron deficiency due to the depletion of iron stores 
or defective iron absorption and limited availability of iron recycled in the reticuloendothelial system.
132, 126 
Although the inflammatory role of elevated hepcidin in HF, which inhibits iron absorption, has been 
hypothesized, recent studies found a rather low-hepcidin profile in HF patients.
133
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The available data establishes a connection between anemia and increased mortality in HF patients, 
nevertheless, it is not unanimous if it is a predictor of mortality or simply a marker of more severe HF.
133 
Anemia has also been related to an increased hospitalization risk.
134, 135
 
The mechanism by which anemia aggravates HF prognosis is not clear, although it seems to be linked to 
increased myocardial workload.
136 
The pathophysiological pathway for progressive iron deficiency in both chronic and acute HF also lacks of 
clarification.
130
 
It appears that HF contributes to myocardial iron depletion and, on the other hand, myocardial iron shortage 
aggravates HF, in a cyclic fashion.
137
 
Our study confirmed that anemia was an independent risk factor for short-term rehospitalization and long-
term mortality.  
Sex thresholds, as described above, further increased the risk for short-term rehospitalization and long-term 
mortality.  
Our findings support the idea that gender adjusted thresholds for anemia may be useful in the estimation of 
outcomes. 
As anticipated, short-term readmission risk, resulting from anemia, was greater in the HFrEF group 
(HR=5.425) than in general population study. 
Importantly, absolute iron deficiency determined an impressive 7.2 increased risk of short-term mortality in 
general population study, in addition, in the HFrEF subgroup elevated serum iron was a protective factor for 
short-term mortality. 
We were able to link other indicators of iron kinetics to some of the proposed outcomes, since a trend 
towards total iron binding capacity (which is increased in iron shortage)
138 
and early rehospitalization was 
detected. 
Albeit customarily iron deficit has been considered to have clinical repercussion only in the presence of 
anemia, some trials proved that it is advantageous to treat iron deficiency in both patients with anemia and 
without anemia. 
A randomized controlled trial of 32 patients with moderate to severe CHF (NYHA class III and IV) with a 
LVEF ≤40%, despite maximally tolerated doses of CHF drugs and whose hemoglobin levels were between 
10 and 11.5 g/dL, indicated that treating anemic patients to a hemoglobin goal of 12.5 g/dL, with 
subcutaneous erythropoietin and intravenous iron resulted in a global improvement of clinical and 
laboratorial profile and was connected with less hospitalization, renal impairment and less need for 
diuretics.
123
 
The Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency (FAIR-HF) trial comprised 
459 ambulatory patients with CHF of NYHA functional class II or III, a LVEF of 40% or less (for patients 
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with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 μg/L or 
between 100 and 299 μg/L, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g/L. 
The treatment arm was submitted to a 24 week intravenous ferric carboxymaltose regimen, either with or 
without anemia (defined as a hemoglobin level ≤120 g/L). 
Along follow-up the intervention group improved symptoms, functional capacity, and the quality of life, 
leading the investigators to propose iron deficiency as a potential therapeutic target. 
The rates of death and adverse events were similar in both arms.
139 
In a study that enrolled 35 CHF patients (with NYHA functional class II or III, ferritin <100 μg/L or 
between 100 μg/L and 300 μg/L with a transferrin saturation <20%; LVEF ≤45%) treated with intravenous 
iron, the authors recognized that in the intervention group, both anemic and non-anemic patients, benefited 
from improved exercise capacity and symptoms, nevertheless benefits were greater in anemic patients.
140
 
A recent study recruited 60 patients with CHF (under optimal treatment), CKD and iron-deficiency anemia. 
At six-month follow-up, the half of the study population that was treated with intravenous iron revealed an 
improvement of CHF symptoms (manifested as a statistically significant change in NYHA functional class) 
and renal function (both P-value <0.001 versus control). 
Concerning biomarkers, the treated arm demonstrated a statistically significant reduction in NT-proBNP 
values at the end of the study. 
Of note, the intervention group also showed a statistically significant increase in the LVEF and a reduction 
in the LV systolic diameter and LV diastolic diameter (P-value <0.01).
141 
The CONFIRM-HF trial (Beneficial Effects of Long-term Intravenous Iron Therapy with Ferric 
Carboxymaltose in Patients with Symptomatic Heart Failure and Iron Deficiency) was a multi-centre, 
placebo-controlled study that gathered 304 ambulatory symptomatic HF patients (nearly equal number of 
patients in NYHA class II and III), with compromised LVEF (≤45%), elevated natriuretic peptides, and iron 
deficiency (ferritin <100 μg/L or 100-300 μg/L if transferrin saturation <20%). 
Treatment with ferric carboxymaltose, during one year, granted a significant reduction in the risk of HF 
hospitalizations and improved symptoms and quality of life, in both anemic and non-anemic patients. 
However, no advantage was noted in relation to death hazard.
142 
 
A recent meta-analysis addressing intravenous iron therapy in iron-deficient patients with HFrEF confirmed 
a reduction in hospitalization rates and improvement in HF symptoms, exercise capacity and quality of 
life.
143 
The EFFECT-HF trial (Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic 
Heart Failure and Iron Deficiency) compared the correction of iron deficiency, with intravenous ferric 
carboxymaltose, to standard of care, in a systolic HF population (LVEF ≤45%) with mild to moderate 
symptoms despite optimal treatment. 
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The investigators focused on peak oxygen consumption (peak VO2), considering that it is a reliable measure 
of exercise intolerance, and concluded that patients’ global assessment and NYHA functional class  
improved in the treatment arm.
144 
Iron deficiency arises, not only as an independent prognostic marker, but also, as an interesting new 
treatment goal for symptom relief in selected HF patients.
130, 137
 
The current ESC guidelines granted ferric carboxymaltose treatment in symptomatic patients with HFrEF 
and iron deficiency, both absolute and functional, in order to relieve symptoms, and improve exercise 
capacity and quality of life, a class IIA recommendation, based on A level of evidence.
1 
 
9.2.3.8. Red Cell Distribution Width 
Red cell distribution width measures anisocytosis, which is the variability in size of the circulating 
erythrocytes.
145
 
The major causes of anisocytosis are impaired erythrocyte production (such as deficiency of hematopoietic 
factors: iron, cobalamin and folate) and increased red cell destruction (namely hemolysis).
145
 
Several conditions (e.g. inflammatory distress, chronic renal failure, nutritional deficiencies, hepatic 
congestion), very common in the HF population, compromise red cell balance.
145
 
Therefore, although not specific, nor directly related to HF pathophysiology, this quotidian overlooked 
parameter seems to identify worse morbid scenarios and therefore correlate with poor prognosis.
145
 
Even though the physiological nexus between RDW and cardiovascular outcomes is not completely 
understood, some authors propose that oxidative stress and chronic subclinical inflammation resulting in 
dysregulation of iron homeostasis could be the cause.
146, 147
 
High baseline RDW has been considered an independent predictor of worse HF prognosis, namely HF 
hospitalization and all-cause mortality, after analysis of data from the CHARM Program and the Duke 
Databank for Cardiovascular Diseases.
145
 
A 2018 investigation also recognize RDW as a long-term predictor of major adverse cardiac events.
148 
Our study seems to support these trials, since RDW correlated with all the proposed outcomes. 
Additionally, in the subset of patients with HFpEF early readmission hazard was inferior to that of the 
general population as predictable. 
We emphasize that mortality risk decreased during follow-up (HR=1.826 for early mortality versus 
HR=1.294 for long-term mortality) which supports our hypothesis that the first 90 days post-discharge 
implicate a maximum risk period that declines with time. 
Likewise the other risk predictors described, the HFrEF subgroup evolved with worse long-term survival 
than general populations’. 
9.2.3.9. Erythropoietin 
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Erythropoietin is a hormone produced in the juxtaglomerular cells of the kidney in response to local hypoxia 
(secondary to renal hypoperfusion) and/or systemic hypoxia (caused by HF, anemia, pulmonary disorders, 
infectious diseases), that promotes erythropoiesis.  
Red blood cell production ensures oxygen delivery to the tissues.
149
 
Therefore, EPO is a marker of hypoperfusion (which is a paramount characteristic of the HF syndrome), 
hypoxia and inflammation, and translates disease severity.
150
 
Beside the hypoperfusion, hypoxia and inflammation scenario, bone marrow resistance to EPO due to iron 
and other hematopoietic factors paucity, often seen in HF patients, could also play a role in EPO’s increased 
production.
151 
The complexity of these mechanisms determine a weak correlation between EPO and hemoglobin values in 
CHF patients, in contrast with other sets of patients.
152 
Consequently, although this hematopoietic growth factor is upregulated in anemic conditions, in CHF 
patients this relation is not linear. 
Such finding may justify the benefit of correcting hematopoietic factors deficit (namely iron deficiency) in 
non-anemic patients. 
High baseline levels of EPO have been described in HF patients by some authors.
152, 153 
Importantly, the relation between HF and heightened EPO values seem to correlate with hospitalization and 
mortality risk. 
Belonje and colleges verified that higher EPO levels were independently linked to HF hospitalization and 
increased mortality risk at 18 months, a follow-up period similar to ours.
153 
A small-scale study of 74 patients with CHF also identified a link between elevated EPO and long-term 
survival.
152 
In our research erythropoietin was a prognosticator of long-term mortality, in accordance to the mentioned 
trials. 
A linkage between EPO and short-term mortality was also encountered. 
Mortality risk diminished along with follow-up, again, supporting our theory that mortality risk peaks at the 
first 3 months after hospital discharge and declines with time. 
For the same increments of EPO, the HFrEF subgroup showed a greater long-term mortality risk than 
general population study, in line with the other prognosticators that we studied. 
A trend-towards short-term readmission and elevated EPO values was recognized in both general population 
study and in HFrEF patients. 
To our knowledge data addressing EPO and HF short-term outcome is scant, thus our study adds some 
information to this matter. 
REFERENCE 
Mário Barbosa     Página | 69  
 
9.2.4. BIOMARKERS 
9.2.4.1. Brain Natriuretic Peptides 
Several biomarkers have been used in HF clinical practice, nevertheless only the brain natriuretic peptides 
are preconized by the current ESC guidelines for the diagnosis of HF.
1 
Although the role of natriuretic peptides as risk stratification markers and its prognostic cardiovascular 
value, specially estimating mortality burden, is gaining importance, the ESC considers that, still, the 
amount of evidence is not sufficient to recommend its use as HF prognosticators.
1 
Considering natriuretic peptide-guided therapy, the controversy of scientific evidence, also, prevent its 
recommendation by the ESC.
1 
On the contrary, in 2013, the American guidelines, already, stated that beside its well validated diagnostic 
indication, B-type natriuretic peptide (BNP) and NT-proBNP can also be applied for prognostication and to 
assess and adjust HF treatment, given that the decline of its serum values correlates with a more favorable 
cardiovascular outcome.
41
  
Beside its diagnostic utility, some authors claim that natriuretic peptides determination is equally suitable to 
estimate prognosis in both acute decompensated HF and CHF.
154 
Brain natriuretic peptide is a hormone first isolated in the brain, nevertheless it is produced by the heart, 
namely the myocytes of the ventricles.  
It is the active product of the cleavage of the prohormone proBNP that, also, generates NT-proBNP which is 
biologically inactive. 
The BNP gene is activated in response to ventricular pressure overload,
155
 which produces the prohormone 
in order to inhibit the renin-angiotensin-aldosterone system, systemic and renal sympathetic activity and 
endothelin-1.
156 
These effects promote natriuresis, diuresis and vasodilation.  
Natriuretic peptides, bradykinin and adrenomedullin are vasoactive endogenous peptides that are subtract to 
neprilysin, an enzyme produced in the proximal tubules of nephrons.
157 
The possibility of preventing cardiac hypertrophy and fibrosis, beside the beneficial natriuretic, diuretic and 
vasodilator effect, through neprilysin blockage has been proposed.
158 
For a long time, it has been postulated that endothelin-1, transforming growth factor-β and angiotensin II act 
as local mediators in cardiac fibrosis.
159 
Tamura N et al., investigated the potential antifibrotic role of BNP, by recognizing that BNP knockout mice 
developed enhanced cardiac fibrosis.
160 
A recent multicenter study, by Miao ZL et al., that encompassed 421 patients with acute myocardial 
infarction submitted to primary percutaneous coronary intervention recognized an improvement in the 
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laboratory panel, cardiac function parameters and cardiovascular outcome in the subset of participants that 
received early intravenous recombinant human brain natriuretic peptide.
161  
The investigators confirmed that the recombinant human brain natriuretic peptide arm showed a significant 
decrease in serum concentrations of Cardiac Troponin T (cTnT) and NT-proBNP, developed an improved 
left ventricular end-diastolic diameter, stroke volume and LVEF, and ultimately cardiac death.
161 
In the opinion of some clinical investigators, natriuretic peptides plasma concentration correlates with the 
severity of systolic dysfunction.
162, 163, 164 
We validated this assumption since NT-proBNP values were inversely proportional to LVEF. 
Researchers from the Framingham Heart Study inferred that most of the variability in NT-proBNP in groups 
of individuals is owed to among-person variability, rather than within-person variability.
 165 
Raymond I et al., had studied the variables on the plasma level of natriuretic peptides, a couple of years 
before, and reached the same conclusions.
166 
Renal impairment increases BNP and NT-proBNP levels because renal clearance represents an important 
mean of their elimination, therefore the correlation between GFR and plasma ranges needs 
standardization.
167 
In our investigation NT-proBNP values were inversely proportional to baseline and admission GFR. 
Regarding the interpretation of natriuretic peptides, in accordance to data from the Framingham Heart Study 
one must consider that its serum concentration tends to augment with age and in women.
165 
In our study no robust correlation was acknowledged regarding gender. 
As for age relation, as referred previously, population homogeneity forbad such inferences. 
In our research the plasma concentration of brain natriuretic peptide was lower in the obese, reproducing 
what was described by Das and colleges.
168 
Apart from the above statements, an interpersonal discrepancy has been denoted as not all HF symptomatic 
patients have increased natriuretic peptides measurements and, on the other hand, not all asymptomatic 
subjects have low serum concentrations.
169, 170 
The American Task Force underlines that although low levels of brain natriuretic peptides have a negative 
predictive value to rule out HF of 96% for BNP and 99% for NT-proBNP and that increased levels have a 
positive predictive value to diagnose HF of 79% and 76%, respectively, one must have in mind that these 
biomarkers are secreted due do ventricular stress and that other etiologies of cardiac injurie beside HF (like 
acute coronary syndromes, atrial fibrillation, myocarditis) and even non-cardiac conditions (namely 
advanced age, renal impairment, anemia and pneumonia) may also determine high levels of these 
peptides.
41 
Therefore, the association with other biomarkers and prognosticators is desired to enhance natriuretic 
peptides’ diagnostic and prognostic efficacy. 
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The association of NT-proBNP to other biomarkers (namely hsTnT, Gal-3 and sST2) added prognostic 
information that will be discussed in the respective sections.  
In our research NT-proBNP was a powerful prognosticator of short and long-term mortality. 
Admission NT-proBNP was a predictor of 90 day post-discharge all-cause mortality, as referred by Waldo 
and collaborators.
171 
We established that admission NT-proBNP was a predictor of long-term overall mortality, as described by a 
substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial, also, 
comprising patients with symptoms of HF at rest or on minimal exertion.
172 
In parallel with a prospective trial addressing ADHF patients, during one-year follow-up, with a year 
mortality close to ours (35%),
173
 we verified that discharge NT-proBNP levels correlated with long-term 
mortality. 
Notably, the mortality hazard associated to elevated admission NT-proBNP was greater in the early post-
discharge period weaning along with follow-up. 
We highlight that elevated discharge values of NT-proBNP posed a greater long-term mortality risk than 
admission concentrations, which supports the utility of serial determinations and that, probably, aiming a 
lowest NT-proBNP as possible during hospitalization could be advantageous. 
Logeart et al., performed serial BNP measurements in patients hospitalized for decompensated CHF and 
recognized that patients that maintained high BNP levels, despite adequate treatment evolved with a worse 
prognosis.
174 
Waldo SW et al. sustained this hypothesis, as discharge values of NT-proBNP showed the greatest 
prognostic yield for all-cause mortality.
171 
Savarese conducted a meta-analysis of 2686 CHF patients that tested natriuretic peptide-guided therapy 
against standard clinically-guided therapy, and found an improvement in mortality and hospitalization rate in 
the peptide-guided therapy group.
175 
Also relevant, was the fact that a meta-analysis proved that serial analysis was useful to optimize HF 
therapy, particularly in the absence of clinical exacerbation.
176 
All these findings corroborate the conjecture that the use of serial natriuretic peptide assays, as performed in 
our study, can add significant information to single measurements. 
We believe that, our findings fundament the utility of NT-proBNP as a predictor of CV outcome beyond its 
well validated diagnostic purpose. 
9.2.4.2. Troponins 
Troponin is a complex of three globular contractile regulatory proteins (troponin T, I and C) situated in the 
thin filament of striated muscle that inhibits contraction through the blockade of the interaction of actin and 
myosin.
177 
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Cardiac troponin I and T exist exclusively in the cardiac muscle, enabling these myofibrillar proteins to be 
specific and sensitive of myocardial injury.
178 
Conversely, type C troponin is found concomitantly in the skeletal muscle, preventing it from being a 
specific cardiac biomarker.
178 
Scientific development granted an improvement in troponin assays through highly sensitive troponin T.
178 
This biomarker warrants a finer detection of cardiac injury than the standard assays, which permits to 
identify minimum cardiac damage. 
Elevated troponin is indicative of cardiomyocyte injury due to any cause, resulting from myocardial stress 
and myocyte death.
179
 
Ischemia is a major cause of myocyte lesion, nevertheless, inflammation, oxidative stress and 
neurohormonal activation also promote cardiac damage.
179
 
Meijers et al., acknowledged that hsTnT has a low biological variation, meaning that even slight variations 
are accurate to identify a real change.
42
  
This feature may render hsTnT appropriate for follow-up and biomarker tailored strategy.
42 
Discrete elevations of troponins are present in HF patients without ischemia, and correlate with death 
hazard, like denoted by Horwich et al.
180 
A prospective study of 107 patients hospitalized with ADHF with similar characteristics to our population 
study (mean age 72 ± 13 years, 44% male and LVEF 47 ± 15%) recognized that hsTnT was an independent 
prognosticator of long-term survival.
181 
Alike the cited trial, we established a consistent relation between hsTnT and long-term mortality risk (P-
value=0.023).  
We emphasize that the long-term mortality risk augmented up to 5 times for a cut-off of hsTnT ≥52 ng/L. 
Pascual-Figal et al., acknowledged that when used together, hsTnT and NT-proBNP provided 
complementary prognostic data and superior risk stratification.
181 
We were able to confirm these observations as hsTnT and NT-proBNP evaluated independently did not 
correlate with early readmission, but when assessed together a link was identified.  
Additionally, the combined evaluation of the myonecrosis marker and of the myocardial stretch peptide 
further increased the long-term mortality risk identified with the evaluation of each biomarker. 
Of interest, the highly sensitive assay identifies a wider range of individuals, including seemingly healthy 
subjects.
182 
This fact raises the possibility of diagnosing subclinical disease, allowing a precocious intervention able to 
change the disease’s course and therefore a more effective primary prevention of CV diseases. 
In the Val-HeFT trial, cTnT was detectable in only 10.4% of the population study while hsTnT was 
perceived in 92% of the population. The elevation of hsTnT was significantly associated with mortality in 
the 90% of the population with undetectable cTnT.
183 
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Such results suggest that hsTnT is a more sensitive predictor of HF survival than cTnT, enabling the 
detection of at-risk patients otherwise neglected by traditional assays. 
Our research supports the idea that hsTnT stands as a more accurate CV outcome predictor as no 
correlations between cTnI and study outcomes were identified. 
The exposed evidence suggests that troponins are more than an acute cardiac injury marker, playing an 
interesting role in the prognostication and risk stratification of cardiac disease and allowing the detection of 
early stage HF. 
Braunwald foresaw, a decade ago, that as the sensibility of troponins perfect, this biomarker would be 
routinely used, in addition to natriuretic peptides, to define prognosis and to monitor response to HF 
treatment.
 179
 
The American HF guidelines recommend cardiac troponin measurement to delineate prognosis of ADHF.
52
 
 
9.2.4.3. Galectin-3 
Galectin-3 is a soluble β-galactoside-binding protein which is produced by activated macrophages. It plays a 
pivotal role in cardiac fibroblast proliferation and collagen synthesis which result in LV stiffness and 
ultimately in ventricular dysfunction.
184, 185
  
Similarly, physiologic myocardium ageing is marked by apoptosis, resulting in decreased cardiomyocyte 
number, collagen deposition and increased cardiomyocyte size. Such cellular changes, seen in the senescent 
heart, promote cardiac fibrotic remodeling and evolve to ventricular diastolic dysfunction.
186 
Fibrosis, the histologic reparation process in which restitutio ad integrum of the injured tissue cannot be 
achieved, being replaced by fibroblasts, seems to be the underlying mechanism of the Gal-3 inflammation 
pathway. 
Although this acute and chronic inflammation marker is not specific of cardiac injury, since it has been 
involved in various organs fibrotic degeneration processes
187
 and even with ageing
188
 and tumor 
mediation
189
 there is growing scientific evidence that consistently support its cardiovascular prognostic 
value. 
The rationale for the utility of Gal-3 in HF clinical practice is based in the fact that the healthy heart 
expresses minimum amounts of Gal-3, which increases as HF progresses
190, 191
 and that, albeit, not being 
specific of myocardium injury, several trials have consistently acknowledged its prognostic value evaluated 
separately or in combination with natriuretic peptides.  
Shah et al., stressed that Gal-3 plasma levels could be elevated, even, in the subclinical phase of HF, which 
could be useful in the assessment of the progression to symptomatic HF and allow a precocious intervention 
in HF management.
192 
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Women
193, 194
 and older patients 
192, 193, 194, 195, 196 
have higher levels of Gal-3,
  
 and one particular study found 
that individuals above 80 years old not suffering from HF frequently have Gal-3 levels superior to 20 
ng/mL. Such conclusions raise the question of establishing cut-offs according to age groups like other 
biomarkers, namely natriuretic peptides.
194 
Patients with greater comorbidity burden, namely obesity, dyslipidemia, arterial hypertension, atrial 
fibrillation
194, 195
 and renal impairment
192, 193, 194, 196
 also presented with higher Gal-3 levels. 
We were able to identify an inversely proportional correlation between Gal-3 levels and GFR for both 
baseline and admission values. 
A trend towards elevated Gal-3 values and ischemic heart disease was also observed. 
In our research no correlation was identified between Gal-3 serum determinations and gender or LVEF, 
findings reminiscent of those of a sub analysis of the Heart Failure: A Controlled Trial Investigating 
Outcomes of Exercise Training (HF-ACTION) study.
197
 
Concerning to NYHA functional class no correlation with Gal-3 was identified by us, likewise the sub 
analysis of the Deventer-Alkmaar heart failure (DEAL-HF) and ProBNP Investigation of Dyspnea in the 
Emergency Department (PRIDE HF) trials.
192, 193, 198, 199 
We are able to verify the assumption of numerous authors that patients with higher serum levels of Gal-3 
have, also, higher levels of brain natriuretic peptides.
192, 193, 194, 195, 196 
Albeit these known interindividual variations, Schindler et al., confirmed that Gal-3 could be a useful tool in 
assessing HF patients due to its low biological variation indices.
200 
Meijers WC et al. observed an association between elevated plasma galectin-3 and near-term readmission 
in HF, as patients with Gal-3 levels greater than 17.8 ng/mL presented twice to three times the risk of 
rehospitalization at 30, 60 and 90 days post discharge, when compared to those who had Gal-3 levels 
inferior to 17.8 ng/mL.
201 
We confirmed that Gal-3 levels correlated with short-term rehospitalization and that the risk increased 
throughout terciles.  
Moreover, the addition of high values of NT-proBNP to Gal-3 further increased the risk of short-term 
rehospitalization. 
In syntony with the addressed prognosticators, the previous multimarker strategy represented a greater risk 
for short-term rehospitalization in the HFrEF group. 
Importantly, galectin-3 was an independent predictor of short-term mortality in our study and, again, the 
combination with NT-proBNP implicated a greater risk than each taken solely. 
The PRIDE sub analysis demonstrated that the subjects who deceased in the first 60 days after hospital 
discharge showed Gal-3 plasma levels superior to those that survived.
198 
The referred study found that Gal-3 was an accurate predictor of mortality and of the binomium 
mortality/recurrent HF.  
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The investigators, also, established that the conjoined use of Gal-3 and NT-proBNP was more sensible to 
prognosticate mortality hazard than each biomarker analyzed separately.
198
 
We acknowledged that Gal-3 was, also, an independent predictor of long-term mortality and that 
multimarker strategy with NT-proBNP perfected risk stratification, as seen in the other proposed endpoints. 
Data from the DEAL-HF study showed that Gal-3 was a reliable mortality predictor in NYHA functional 
class III and IV patients, since a proportional increase in all-cause mortality was noted throughout the Gal-3 
quartiles.
193 
The sub analysis of the Coordinating Study Evaluating Outcomes of Advising and Counseling Failure 
(COACH) trial noticed that the prognostic efficacy of the combination of Gal-3 and BNP (AUC 0.69) was 
superior to Gal-3 alone (AUC 0.67), which was greater than BNP’s evaluated individually (AUC 0.65).195 
Galectin-3 proved to be an interesting biomarker in our research as it prognosticated all the aimed outcomes. 
Remarkably we achieved statistical significance using a cut-off lower than the generally preconized, 
nevertheless the serum values of Gal-3 vary with the quantification method, which prevents direct 
comparison with studies that used a different lab kit. 
The current data supports that although Gal-3 has a diagnostic value inferior to the traditional natriuretic 
peptides, when assessed separately its prognostic role looks to be superior, achieving an even greater 
accuracy when both biomarkers are analyzed together.  
The weight of evidence suggests that Gal-3 is a useful tool to detect and stratify high risk HF patients, 
enabling to plan their follow-up, in order to reduce the notorious high rates of near-term rehospitalization 
and mortality. 
The sum of relevant evidence led the 2013 American guidelines to recommend the measurement of Gal-3 
for additive risk stratification in patients with acute or ambulatory HF.
41
 
Even though the Gal-3 extracellular releasing mechanism needs clarification, there is substantial evidence 
linking this inflammation surrogate marker to cardiac remodeling and ultimately to HF inexorable 
continuum. 
Given this, one must question if in a near future Gal-3 suppressors or inhibitors of its pathways will ascend 
as new cardiovascular therapeutic targets. 
9.2.4.4. Pro-ADM 
The role of mid-regional pro-adrenomedullin in the management of HF urges clarification, yet the available 
data support its application as a trustworthy biomarker of short and long-term prognosis in both 
decompensated and stable chronic HF. 
Nevertheless, the scientific evidence favors short-term assessment. 
Concerning diagnosis its accuracy seems to be doubtful. 
Adrenomedullin is a 52-amino acid peptide discovered in pheochromocytoma cells in the adrenal medulla.
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It is a ubiquitous peptide and apart from the heart it is also produced by several other tissues namely 
endothelial cells, vascular smooth muscle cells, fibroblasts, adipocytes.
202, 203
 
The main organs (central nervous system, kidneys, lungs, gastrointestinal organs) also secret ADM. 
Considering the myocardium, ADM expression is stimulated by pressure or volume overload and ventricular 
wall stretching, counteracting with a reduction in preload and afterload by promoting diuresis, natriuresis 
and vasodilation.
202, 203 
An additional cardioprotective benefit has also been hypothesized, as it has been related to a reduction in 
cardiac hypertrophy, ventricular remodeling and fibrosis.
202, 203
 
Thus ADM’s role in HF’s pathophysiology is based in the fact that it is a cardiomyocyte strain marker with 
vasoactive properties.  
The cleavage of pro-hormone pro-ADM originates ADM and MR-proADM.
202, 203 
Direct quantification of ADM is not feasible due to its in vitro instability, short half-life and the existence of 
binding proteins. However MR-proADM besides being stable, allowing dosing, correlates with ADM levels.
 
202, 203, 204 
Likewise other HF markers MR-proADM is elevated in other cardiovascular pathologies (myocardial 
infarction, systemic and pulmonary hypertension) and even in non-cardiologic conditions (kidney failure 
and sepsis).
202, 203 
Data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-HF (GISSI-HF) 
trial, which comprised 1237 patients with chronic and stable HF, suggested that as with natriuretic peptides, 
one must bear in mind that MR-proADM serum concentration augments with ageing, systolic dysfunction 
and renal impairment. Similarly, the female gender has heightened levels and individuals with higher body 
mass index show decreased MR-proADM values.
205
 
Furthermore, MR-proADM interpretation is compromised by the absence of a well-established threshold. 
In our research a trend towards MR-proADM values and NYHA functional class IV was observed. 
Von Haehling et al., addressed 501 CHF patients, and verified, too, that MR-proADM plasmatic levels 
increased with NYHA class.
206 
We point out that in HFmrEF patients a trend towards MR-proADM and early readmission was identified, 
since that, to our knowledge data addressing this topic is limited. 
We relied on several trials to pursue relevant data regarding this new biomarker, nevertheless our results 
were somehow frustrating as no statistically significant result was achieved, possibly due the reduced 
member of participants in our study. 
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9.2.4.5. ST2 
Suppression of tumorigenicity 2 is a promising biomarker that seems to correlate more accurately with 
cardiovascular remodeling and fibrosis than MR-proADM, beside its precision in estimating the outcome of 
HF, improving natriuretic peptides’ performance. 
There is consistent evidence that suggests that its biologic variability is considerably lower than that of the 
natriuretic peptides, which could warrant a greater prognostic sensibility.  
Head-to-head comparison of ST2 and Gal-3 in CHF risk stratification seems to favor ST2 over Gal-3.
207 
Concerning diagnosis, as with MR-proADM, its value appears to lack significance.  
The 2013 American guidelines recommend the measurement of ST2 for additive risk stratification in 
patients with acute or ambulatory heart failure.
41 
Suppression of tumorigenicity 2 belongs to the IL-1 receptor family. There are two main isoforms, a 
transmembrane receptor (ST2L) and a soluble receptor (sST2) which is the circulating isoform that can be 
detected in serum.
208, 209 
The pathophysiological role of this biomarker in HF, is based in the cardioprotective effect of the interaction 
of ST2L and its ligand, IL-33, a cytokine released in response to cellular damage, including cardiomyocyte 
strain.
208, 209 
This pathway regulates the myocardial reaction to biomechanical overload in strained cardiac fibroblasts and 
cardiomyocytes, resembling natriuretic peptides function.
210 
The duality IL-33/ST2L, participates in several inflammatory conditions, beyond cardiac distress, by 
triggering Th2 effector cells which secretes cytokines.
208 
It has been postulated that the IL-33/ST2 pathway, although unspecific, is expressed in cardiac fibroblasts 
and cardiomyocytes due to myocardial damage.
208, 209
 
Its beneficial cardiac effect derives from the counterbalance of cardiac apoptosis, myocardial fibrosis, 
cardiomyocyte hypertrophy, and ultimately, by increasing myocardial function.
208, 209
 
This advantageous effect is abrogated by the soluble isoform, which acts as a decoy receptor, by binding to 
IL-33 and blocking its signaling.
208, 209, 211 
Thus, the rationale of using sST2 as HF biomarker relies on the fact that its levels are increased in 
cardiomyocyte damage, namely remodeling, fibrosis and hypertrophy.
208, 209 
It has been stated that sST2 evaluation could play a role in the assessment of ventricular remodeling since 
elevated serum concentrations reliably correlate with reduced ejection fraction, left ventricular enlargement 
and hypokinesia.
212 
In addition, a link between this marker and left ventricular end-diastolic volume was recognized, raising the 
possibility of monitoring structural cardiac modifications.
213 
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Similarly to the other discussed biomarkers sST2 is not specific to HF, and rises in other cardiovascular 
conditions like ischemic and valvular heart disease and arterial hypertension.
211 
Given this, sST2 lacks disease specificity and, consequently, is a poor marker for the diagnosis of HF.
211 
Nevertheless, like galectin-3 and MR-proADM, it seems to be useful in stratifying both acute and chronic 
HF severity and determining the prognosis.
211 
This novel biomarker emerges as an independent predictor of mortality, in both acute and chronic HF, 
irrespective of the etiology of HF or LVEF, and as a complement to other markers.
214 
Likewise the natriuretic peptides and MR-proADM, sST2 levels vary inversely with the GFR, but its 
prognostic accuracy does not seem to be compromised by renal function.
215, 216, 217
 
We verified that sST2 levels correlated inversely with baseline and admission GFR (P-value<0.001 for 
both). 
Nonetheless, according to Rehman S et al., these associations were weaker than those related to natriuretic 
peptides’, raising the hypothesis that sST2 prognostication sensitivity is not significantly influenced by 
comorbidities.
215 
Piper S et al., also documented that the biologic variability of sST2 is substantially inferior to that of 
natriuretic peptides, thus more precise, alluding that this molecule could represent a breakthrough in CHF 
assessement.
218 
As for age, like defended by Rehman S et al.,
215
 no consistent correlation was identified in our investigation. 
Some authors suggest that greater sST2 values are present in the male gender.
213, 217 
In our investigation a trend towards sST2 levels and male patients was also identified. 
The Metabolic Efficiency With Ranolazine for Less Ischemia in the Non-ST-Elevation Acute Coronary 
Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) trial stressed the eventual 
necessity of defining gender-based thresholds.
219 
Similarly to NT-proBNP, obese patients had lower amounts of sST2 in our study. To our knowledge data 
establishing a statistical significant relation between sST2 and obesity is scant.  
Such finding could be interpreted as since sST2 elevation is a marker of worse outcome, and in our study the 
obese evolved with a better long-term survival, it is reasonable that these two variables vary inversely. 
Furthermore, sST2 elevation was, also, a predictor of long-term mortality. 
Although the prognostic cutoff of 35 ng/mL is widely accepted,
213, 217, 219 
there is still some argument 
surrounding the ideal sST2 upper reference limit for cardiovascular risk stratification.
 
Our investigation adds controversy to this discussion as we were able to establish a lower threshold of 24.78 
pg/mL, with a significant 5 times increased hazard for long-term mortality. 
Additionally, for each increment of, as little as, 10 pg/mL of sST2 the risk for long-term mortality elevated 
up to 37.2%. 
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However the different methods of quantifying sST2 are not directly comparable and it is essential to know 
which method was used when interpreting the results.
220 
A cohort of 346 patients with ADHF, by Rehman et al., corroborated the relation between heightened levels 
of sST2 and poor long-term outcome (the AUC ROC for death at 1 year was 0.71).
215 
Our finding is, also, sustained by the PRIDE trial, since a trend towards high concentrations of this 
biomarker and one year-mortality was acknowledged.
221
  
Relevantly, the mutual quantification of sST2 and NT-proBNP improved risk stratification.
221 
The association of NT-proBNP to sST2 determination was also useful in our study as it further increased the 
long-term mortality risk. 
Subgroup analysis showed that, for HFpEF patients, the addition of serum values of admission NT-proBNP 
≥1800 ng/L to sST2 ≥24.78 pg/mL further increased the hazard of long-term mortality compared to the 
individual evaluation of sST2 (HR=5.2 Vs HR= HR=8.381, respectively). 
Rehman and colleges were, also, able to recognize that both sST2 and NT-proBNP were powerful 
prognosticators of long-term mortality.
215 
Notably, the patients with simultaneous elevation of sST2 and natriuretic peptide had a higher mortality 
burden.
215 
Remarkably the addition of Gal-3 values ≥9.99 ng/mL to sST2 assessment implicated a 6 times augmented 
long-term mortality hazard, which was comparable to the conjoined evaluation of sST2 and admission NT-
proBNP ≥21336 ng/L. 
We underscore that, resembling other multimarker strategies discussed in this research, long-term mortality 
risk linked to sST2 and Gal-3 simultaneous quantification, was greatest in the HFrEF and lowest in the 
HFpEF. General population study showed an intermediate risk. 
We could not achieve a link between sST2, nor with Gal-3 ≥9.9 ng/mL, and early mortality when each 
biomarker was assessed isolatedly, however with their combination statistical significance was met. 
The combination of sST2 ≥24.78 pg/mL and Gal-3 ≥9.99 ng/mL implicated an interesting 8 times increased 
hazard for early mortality. 
Subgroup analysis showed that in the HFpEF subset of patients, joining determinations of sST2 ≥24.78 
pg/mL and Gal-3 ≥10.97 ng/mL resulted in an impressive HR of 19.3. 
Although there are several studies relating sST2
215, 53 
and Gal-3 to short-term mortality separately
198 
to our 
understanding studies focusing on a multimarker approach regarding this outcome lack. 
Therefore our research brings new information to this topic. 
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10. STUDY LIMITATIONS 
Although the authors followed the patients thoroughly, the rehospitalization rate may not be 100% accurate 
as some patients could be readmitted into a different hospital. However, we believe that such cases were 
trivial since that the area code hospital of the population was the Hospital de Santa Maria. 
The present trial is hindered by the fact that the population was relatively small, making some appraisals 
problematic without accurate statistical power.  
To analyse the prognostic precision of each biomarker and to implement a multibiomarker strategy,  specific 
cut-offs were defined, however some thresholds are not standardized and different methods of quantifying 
some biomarkers are not directly comparable which has to be taken into account when comparing to other 
studies. 
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11. STRATEGIES TO DECREASE READMISSIONS AND MORTALITY 
In a study, conducted by Sousa-Pinto, all hospitalizations in public hospitals in Portugal mainland from 2000 
to 2008 were analyzed, aiming to describe non-planned hospital readmissions occurring in a period of 30 
days post-discharge.
28
 
The aforementioned research apart from studying the rate evolution of readmissions in that period, focused, 
specifically, on readmissions related to ADHF.  
Special attention was paid to HF due to its high socio-economic impact
222 
related to the high risk of 
readmission and because scientific evidence demonstrated that the implementation of strategies directed to 
patients with this illness decreases the readmission episodes
223, 224
. 
At the time this report was a breakthrough as there were no similar studies in Portugal.
28
 
From the 5 514 331 non-elective hospitalizations occurring in the studied period, 4.1% corresponded to 
readmissions. 
The nosological entities were grouped in large diagnostic categories; a larger readmission rate was verified 
in the group of “Myeloproliferative Diseases & Disorders, Poorly Differentiated Neoplasms”. 
This heterogeneous nosological group encompasses hematological neoplasms, occult malignant cancers and 
cancer metastasis, which due to its clinical severity and inherent side effects related to the targeted therapy 
(namely chemotherapy, radiotherapy and immunosuppressants) a high number of readmissions is 
expected.
28
 
Minding this fact, we excluded patients with active neoplasm so that it would not bias the readmission rate 
in our investigation. 
In the specific case of HF (n = 315 321) the rehospitalization rate was of 6.7%, below the rates reported in 
similar studies.  The authors justified this lower than expected readmission rate with fact that the patients’ 
identification code kept changing from year to year  in the same hospital and some patients were readmitted 
into a different hospital.
28
 
During the period 2000 to 2008, the rate of readmissions due to HF increased significantly. In relation to in-
hospital mortality there was also an increase in the given period, both in the readmitted and non-readmitted 
group, with no significant difference between groups (17.2% vs. 16.9% respectively), although a greater 
increment was found in the readmitted group.
28
 
The authors argued that the data provided by their study could be used by the Portuguese National Health 
System to improve hospital organization and therefore reduce the readmission burden. 
Several healthcare programs have been applied to monitor HF outcome, nevertheless most were small and 
underpowered, the targeted populations were not homogeneous and the strategies varied widely among 
studies which prevents us from inferring its real impact. 
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Unfortunately, one must agree that evidence addressing multidisciplinary approach to the HF population is 
still scarce and lacks statistical power. 
A close follow-up is essential to identify and treat slight acute decompensations, preventing progressive 
deterioration and consequent hospitalization. 
A document elaborated by the National Heart Foundation of Australia defined a set of principles addressing 
care delivery, to enhance health professionals’ practice, aiming at improving CHF patients’ quality of life 
and avoid hospitalizations.
225 
The Australian Task Force carried out a systematic review of randomized trials evaluating multidisciplinary 
strategies for the management of HF patients at high risk for admission, and concluded that in-person 
specialized follow-up at home or in a healthcare facility reduced HF hospitalizations, all-cause 
hospitalizations and mortality.
225 
Patients that were contacted by telephone on a regular basis by their physician had less HF hospitalizations, 
although no difference in all-cause hospitalizations or mortality was found.
225
 
A meta-analysis by Foody et al. validated the positive impact of structured telephone support in HF 
readmission, plus HF mortality.
226 
Regarding telemonitoring programs, in which data (symptoms, physiologic parameters) is remotely 
transmitted to the healthcare providers, without visits by the health personnel or direct phone calls, there is 
some controversy as some meta-analysis mentioned a trend towards reduction in HF hospitalizations and 
mortality,
227
 while others found no benefit in the outcome
226, 228
. 
Patient awareness is fundamental to promote self-care.  
The Australian Task Force also verified a decrease in HF hospitalizations and all-cause hospitalizations in 
healthcare programs focused on self-care, but no significant impact on mortality was identified.
225 
An observational study of almost 11 000 patients sustained that patients revaluated within the first 30 days 
post-discharge by both a primary care physician and a cardiologist had a significant lower one year-
mortality compared to those observed solely by a primary care clinician. For the given period of time 
patients evaluated only by a generalist had a lower mortality rate than patients with no post-discharge 
assistance at all.  
The results were explained by the fact that patients cared by both a specialist and a generalist had LV 
function assessment more often and were more likely to be treated with evidence-based drugs.
229 
Nowadays there has been a consistent proliferation of multidisciplinary HF clinics (the so called “infusion 
centers”) that administer intravenous drugs, either diuretics or ionotropics, to outpatients. 
A meta-analysis including forty-seven trials addressing healthcare programs enrolling predominantly 
patients with moderate to severe HF with a mean age of 70 years, confirmed a clear benefit in three- to six-
month readmission and mortality rates when such patients were treated in these clinics.
230 
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An observational study demonstrated that hospitals with the lowest early post-discharge reexamination rate 
(within the first week) had a 3% higher 30-day re-hospitalization incidence compared to those that were 
prone to early post-discharge appointment.
231 
The Portuguese Consensus Statement for the improvement of HF, preconized a multidisciplinary 
management of HF patients,
21
 since specialized HF multitask teams have proved to be cost-effective and to 
improve patients’ outcome by reducing admissions and mortality1. 
Beside health care professionals recommendations, the Statement also focuses on patient and care giver 
education.
21
 
The Portuguese Task Force
 21 
also suggested, in syntony with the latest European HF guidelines
1
, an early 
post-discharge reevaluation, ideally after one week by a primary care physician and, at most, after two 
weeks by a specialist. 
The Statement also stresses the crucial importance of HF Day-Hospitals and cardiac rehabilitation programs 
in todays´ long-term patients’ approach, earning a class IA from the actual guidelines1, emphasizing the 
necessity of creating more specialized ambulatory centers in Portugal.
21
 
Portugal is one of the 45 countries, that integrates the Optimize Heart Failure Care Program (www.optimize-
hf.com), implemented worldwide, since 2013.
232 
This Program aims at improving outcomes following HF hospitalization through inexpensive initiatives to 
optimize
 
prescription of evidence-proved drugs, patient and care givers instruction and involvement, and 
post-discharge planning.
 
The Program provides best practice clinical protocols based on the latest ESC guidelines
1
, pre- and post-
discharge checklists, and ‘My HF Passport’, a printed and smart phone application to improve patient 
knowledge of CHF and promote involvement in care adherence. 
The ‘My HF Passport’ also allows the patient to register relevant signs and symptoms, granting the 
physician the opportunity to optimize the treatment. 
Its purpose is to guarantee that the in-hospital measures are continued post-discharge, particularly in the 
most vulnerable period of the first months.
232 
‘Get With the Guidelines-Heart Failure’ (GWTG-HF) is an in-hospital program, sponsored by the AHA, for 
improving care through promoting adherence to guidelines.  
This registry is the continuation of the Organized Program to Initiate Lifesaving Treatment in Hospitalized 
Patients with Heart Failure (OPTIMIZE-HF) program
233
 that resembles the European program. 
There is evidence that the Program implementation resulted in 30-day readmission for HF reduction,
234
 still 
an USA national survey evidenced that the adherence can be furthermore improved
235
. 
As advocated the first 30 to 90 days post-discharge is a critical period for HF patients and should be an 
opportunity to intervene and try to change the syndrome’s course. 
REFERENCE 
Mário Barbosa     Página | 84  
 
Since it is not viable to reevaluate all the HF hospitalized patients in this strict period of time, it is 
mandatory to identify and target high risk patients for early readmission and mortality and be assertive in 
this “golden period”. 
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12. CONCLUSIONS 
According to our study, the risk factors for early readmission were: the accumulated length of stay, multiple 
hospitalizations, renal failure, cardiorenal syndrome, RBBB, anemia, elevated RDW and Gal-3 values. 
We acknowledged the following risk factors for early mortality: the absence of inferior vena cava 
inspiratory collapse, increased LV end-diastolic volume, hepatomegaly, low systolic and diastolic blood 
pressure, renal failure, cardiorenal syndrome, LBBB, absolute iron deficiency, elevated RDW, EPO, NT-
proBNP and Gal-3 determinations.  
The combination of biomarkers added relevant data, namely the addition of sST2 to Gal-3 which further 
increased the risk for early mortality. 
Small sample size forbad significant statistical correlation between the defined outcomes and the etiology of 
HF, the NYHA functional class, therapeutics and the biomarker Pro-ADM. 
We believe that this trial could contribute to risk-stratify heart failure patients, as several variables were 
addressed from symptoms, to electrocardiography, echocardiography, routine lab tests and ultimately new 
era biomarkers. 
Our results may raise, simultaneously, the interest in some neglected quotidian parameters and in novel 
biomarkers. 
National data regarding this matter is scant, so this study may help to better understand our heart failure 
population.  
The conclusions provide real world data, as it was collected from a subset of patients randomly hospitalized 
for acute decompensated chronic heart failure in an Internal Medicine ward, and similar findings were 
reported in larger and multicenter investigations, which corroborate and in a certain way validate the results.  
Given its complexity, strategies to reduce heart failure rehospitalization and mortality should encompass the 
optimization of evidence-based treatment, addressing assertively the etiology of heart failure and 
concomitant comorbidities, tight follow-up (a multidisciplinary approach and first and foremost the 
widespread of Heart Failure Day-Hospitals to stabilize patients with minor decompensations preventing the 
worsening of the condition and inevitably the admission to ward) and patient education.  
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CONSENTIMENTO INFORMADO, LIVRE E ESCLARECIDO PARA PARTICIPAÇÃO EM 
INVESTIGAÇÃO* 
 
Título do estudo: DETERMINANTES DA READMISSÃO PRECOCE NA INSUFICIÊNCIA CARDÍACA CRÓNICA 
 
O actual projecto de Investigação insere-se num estudo que decorre no âmbito do Mestrado em Doenças 
Metabólicas e Comportamento Alimentar da Faculdade de Medicina da Universidade de Lisboa e tem como 
principal objectivo caracterizar os doentes de risco para readmissão precoce por insuficiência cardíaca 
(definida como reinternamento até aos 90 dias pós-alta), a fim de, perante os resultados obtidos, poderem ser 
consideradas estratégias que permitam reduzir as readmissões e melhorar o prognóstico. 
Venho desde já agradecer a sua colaboração neste projecto de investigação, que espero aceite participar. 
Para tal iremos necessitar de colher uma mostra de sangue para exames laboratoriais e consultar o seu 
processo arquivado no Serviço de Medinica I D.  
Por este motivo a sua participação, disponibilizando a consulta anonimizada do seu processo e alta, é 
fundamental. 
Este projecto não lhe trará nenhuma despesa ou risco. Qualquer informação será confidencial e fornecida de 
forma anonimizada através de um médico do serviço (equipa do Prof. Doutor Luiz Filipe Menezes Falcão) 
não sendo revelada a terceiros. A informação recolhida poderá eventualmente ser publicada em Revista 
Médica da especialidade, sem possibilidade de identificação do doente. 
A sua participação neste projecto é voluntária e ser-lhe-á dada sempre a possibilidade de alterar o sentido da 
sua declaração de participação ou recusar participar, sem que tal tenha consequências para si. 
Caso pretenda participar no projecto, assine o documento 
Pode contactar-me para o seguinte número __________________ 
Por favor não hesite contactar-me para qualquer Informação adicional que necessite. 
Muito obrigado 
 
Nome do investigador: Dr. Mário Barbosa 
 
Assinatura: _____________________      Data: ___/___/_____ 
  
 
Declaro ter lido e compreendido este documento, concordo em participar no projecto de forma voluntária, 
anónima e confidencial  
 
Nome:_______________________________________________________  
 
Assinatura: _____________________      Data: ___/___/_____  
 
*de acordo com a Declaração de Helsínquia e a Convenção de Oviedo
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REGISTO DO DOENTE 
 
NID: ____________________ 
Serviço: _________________ 
Nome Completo: ____________________________________________ 
Idade: ___ anos 
Data de Nascimento: __/__/____ 
Sexo:  M   F 
Raça:  Caucasiana   Negra  Indiana Outra  
Morada (com CP): _______________________________________________________ 
Telefone/Telemóvel: ___________________________ 
Telefone/Telemóvel (familiar): ___________________ Parentesco: _____________ 
Causa de Internamento: 
Data de Internamento: __/__/____ 
Internamento:  Cardiologia  Medicina Interna  Outro 
Peso: ____________________ 
Altura: ___________________ 
IMC
1
: _____________________ 
Superfície Corporal
2
: ________________ 
Fórmulas 
1
IMC = Peso [kg]/Altura
2
 [m] 
2 
Fórmula de Dubois da Superfície Corporal (m
2
) = 0,007184 X ( Altura [cm])
0,725
 X ( Peso [kg] )
0,425
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SINAIS E SINTOMAS DE INSUFICIÊNCIA CARDÍACA
3
 
 
CRITÉRIOS MAJOR 
Dispneia paroxística nocturna:    Sim  Não 
Ortopneia:       Sim  Não 
Ingurgitamento venoso jugular:     Sim  Não 
Fervores crepitantes:      Sim  Não 
Cardiomegália (RX tórax – ICT):     Sim         ICT:______ Não 
Edema pulmonar agudo:      Sim  Não 
Galope ventricular (S3):      Sim  Não 
Refluxo hepato-jugular:      Sim  Não 
Dispneia em repouso:      Sim  Não 
 
CRITÉRIOS MINOR 
Edema maleolar:      Sim  Não 
Tosse nocturna:       Sim  Não 
Dispneia de esforço:      Sim  Não 
Hepatomegália:       Sim  Não 
Derrame pleural:      Sim   Não 
Taquicardia sinusal (≥120bpm):    Sim  Não
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CRITÉRIOS MAJOR OU MINOR  
Perda de peso > 4,5Kg em 5 dias como resposta terapêutica:  Sim   Não 
 
PÂRAMETROS VITAIS 
TA: 
FC: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nota 
3 
ICC confirmada: se 2 critérios major ou 1 critério major + 2 critérios minor
Faculdade de Medicina de Lisboa Página 4 
 
 
Questionário base de dados 2015 
 
ANTECEDENTES PESSOAIS 
 
Cardiopatia isquémica:    Sim  Não 
EAM prévio:      Sim     Não 
Doença valvular:     Sim  Não 
Cardiopatia hipertensiva:   Sim  Não 
HTA:       Sim  Não 
DM2:      Sim   Não 
Dislipidemia:     Sim         Não 
Tabagismo:     Sim            Não 
Insuficiência renal crónica:    Sim    Não 
Doença vascular:     Sim  Não 
DPOC:      Sim       Não 
História familiar:     Sim  Não  Ignora
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EXAMES COMPLEMENTARES 
 
Ureia (basal/ internamento): _____ /____ 
Creatininémia (basal/ internamento): _____ /____ 
Clearance creatinina (basal/ internamento): ____ /____ 
Hemoglobina: ___________ 
VGM: ______________    RDW:  _____________             
Plaquetas: _______  Plaqueócrito:________   VPM:   _______              PDW: ______ 
Natrémia: ____________ 
TSH: ________________ 
FT4: ______________ 
Fe sérico: __________ 
Ferritina sérica:  ________ 
Saturação da transferrina:  ___ 
CTFF: ______________ 
Galectina-3: __________       MR-proADM:_________ 
ST2:    __________________         EPO:____________ 
NT-proBNP da entrada: __________ 
NT-proBNP da alta: __________ 
hsTnT: ____________         TnI:   __________ 
ECG*:  RS       FA           BCRE         BCRD      HVE    FLA  PMD   
           EAM        localização: __________ 
 
 
*Surawicz B, Childers R, Deal BJ, Gettes LS. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation 
of the ElectrocardiogramPart III: Intraventricular Conduction Disturbances A Scientific Statement From the American Heart 
Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of 
Cardiology Foundation; and the Heart Rhythm Society Endorsed by the International Society for Computerized 
Electrocardiology. Journal of the American College of Cardiology. 2009;53(11):976181. 
       
Faculdade de Medicina de Lisboa Página 6 
 
 
Questionário base de dados 2015 
 
Ecocardiograma:     Normal   
           RAO     __________mm 
         IRAO        __________mm/m
2
 
           AE MM        __________mm 
          IAE MM        __________mm/m
2
 
           Área AE        __________cm
2
 
           Volume AE    __________ml  _________ml/m
2
 
          Área AD     __________cm
2
 
           Volume AD   __________ml        _________ml/m
2
 
           DTDVE       __________mm 
           IDTDVE        __________mm/m
2
 
           DTSVE        __________mm 
           IDTSVE        __________mm/m
2
 
           FENC         __________% 
          SIV        __________mm 
           PP        __________mm 
           VD       __________mm 
           VTDVE        __________ml 
           IVTDVE       __________ml/m
2
 
           VTSVE       __________ml 
          IVTSVE       __________ml/m
2 
           FEJ        __________% 
           MVE
4
        __________g 
           IMVE
5
       __________g/m
2
 
           PSAP        __________mmHg 
           VCI diâmetro __________cm 
           Vel maxE       _________m/seg 
           Vel maxA       _________m/seg 
           E/A        __________ 
           RWT
6
        __________ 
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Disf. Diastólica:    tipo I     _______ tipo II       _______     tipo III         ______ 
Insuf. Aórtica moderada:    Sim  Não 
Insuf. Aórtica grave:     Sim            Não 
Estenose Aórtica moderada:    Sim       Não 
Estenose Aórtica grave:     Sim   Não 
Insuf. Mitral moderada:     Sim       Não 
Insuf. Mitral grave:      Sim          Não 
Estenose Mitral moderada:     Sim            Não 
Estenose Mitral grave:     Sim          Não 
Insuf. Tricúspide moderada:    Sim      Não 
Insuf. Tricúspide grave:     Sim      Não 
Prótese valvular Aórtica:    Sim            Não 
Prótese valvular Mitral:     Sim            Não 
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Fórmulas 
4
MVE (Devereux modificada)(g) = 1,04 x [ (DDVE+SIVD+PPVED)
3 
- DDVE
3 
] – 13,6 
5
IMVE (g/m
2
)= MVE/superfície corporal 
 
6
Relative Wall Thickness (RWT) ou Índice de Hipertrofia Concêntrica= (2xPP)/DTDVE 
TABELA – Valores ecocardiográficos adaptados de várias tabelas, nomeadamente, LANG RM, BIERIG M, 
DEVEREUX RB ET AL. RECOMMENDATIONS FOR CHAMBER QUANTIFICATION: A REPORT FROM 
AMERICAN SOCIETY OF ECHOCARDIOGRAPHY’S GUIDELINES AND STANDARDS COMMITTEE AND THE 
CHAMBER QUANTIFICATION WRTITING GROUP, developed in conjunction with the European Association of 
Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiog 2005;18:1440.  
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Valores de 
Referência 
Mínimo Máximo 
RAO mm 22 36 
IRAOmm/m
2 
< 21  
AE MM mm 27 40 
IAE MM mm/m
2 
15 23 
AE área cm
2
 <20  
AE vol  ml 18 58 
AE vol ml/m
2
 22 ±6  
AD área cm2  <20  
AD vol  ml  18 58 
AD vol ml/m
2 
 22 ±6  
DTDVE mm 39 59 
IDTDVE mm/m
2
 22 32 
DTSVE mm   22 35 
IDTSVE mm/m
2
   11 21 
FENC %  32 53 
Esp SIV mm 6 10 
Esp PP mm 6 10 
VD mm 20 28 
VTDVE ml 56 155 
IVTDVE ml/m
2
 35 75 
   
VTSVE ml 19 58 
IVTSVE ml/m
2
 12 30 
FEJ % ≥55%  
MVE gr 66 200 
IMVE gr/m
2
 44 102 
PSAP  mmHg 17 32 
VCI diâmetro cm ≤21  
Vel maxE m/seg 0,4 1 
Vel maxA m/seg 0,3 1,1 
E/A 0,6 2 
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FÁRMACOS DO INTERNAMENTO 
 
IECA (dose):    Sim 
Captopril: __________ 
     Enalapril: __________ 
     Lisinopril: __________ 
     Perindopril: __________ 
     Ramipril: __________ 
     Trandolapril: __________ 
     Não 
     Interrompido  
 
ARA II (dose):   Sim 
Losartan: __________ 
Candesartan: __________ 
     Valsartan: __________ 
     Outro: __________ 
     Não 
     Interrompido 
 
Beta-bloqueantes (dose):     Sim  
Bisoprolol: __________ 
Carvedilol: __________ 
     Metoprolol: __________ 
     Nebivolol: __________ 
     Atenolol: __________ 
     Não 
     Interrompido  
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Diurético de ansa (dose):    Sim  
Furosemida: __________ 
Não 
       Interrompido  
 
Diurético tiazídico (dose):    Sim 
Hidroclorotiazida: __________ 
       Metolazona: __________ 
       Indapamida: __________ 
       Clortalidona: __________ 
Não 
       Interrompido  
 
Antagonista dos mineralocorticóides (dose):   Sim  
Espironolactona: __________  
Eplerenona: __________ 
Não 
Interrompido 
 
 
Ivabradina (dose):   Sim    Não       Interrompido 
 
Digoxina (dose):  Sim       Não  Interrompido  
 
Dobutamina (dose):  Sim        Não  Interrompido  
 
Dopamina (dose):  Sim       Não  Interrompido  
 
Noradrenalina (dose):  Sim        Não  Interrompido  
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Antiagregação plaquetar:    
 
Aspirina 100mg  Sim 
   Não 
   Interrompido 
 
Clopidogrel 75mg Sim 
   Não 
   Interrompido 
 
Ticagrelor (dose):      Sim   
                                 Não   
           Interrompido 
 
Anticoagulação oral (dose): Sim 
    Varfarina ___________ 
      Dabigatrano __________ 
    Rivaroxabano ___________ 
    Apixabano ___________ 
    Edoxabano ___________ 
    Não 
    Interrompido
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DIAGNÓSTICO DE IC NO INTERNAMENTO ACTUAL 
Sim 
Não 
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FÁRMACOS PARA A ALTA 
 
IECA (dose): Sim 
Captopril: __________ 
  Enalapril: __________ 
  Lisinopril: __________ 
  Perindopril: __________ 
  Ramipril: __________ 
  Trandolapril: __________ 
  Não 
 
ARA II (dose): Sim 
Losartan: __________ 
Candesartan: __________ 
   Valsartan: __________ 
   Outro: __________ 
   Não 
 
Beta-bloqueantes (dose):    Sim  
Bisoprolol: __________ 
    Carvedilol: __________ 
    Metoprolol: __________ 
Nebivolol: __________ 
    Atenolol: __________ 
    Não 
 
Diurético de ansa (dose): Sim  
Furosemida: __________ 
Não 
 
 
 
 
 
  
 
Antagonista dos mineralocorticóides (dose):   Sim  
Espironolactona: __________  
Eplerenona: __________ 
Não 
 
Ivabradina (dose):   Sim   Não  
 
Digoxina (dose):  Sim        Não 
 
 Questionário base de dados 2015 
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Antiagregação plaquetar:    
 
Aspirina 100mg  Sim 
   Não 
 
Clopidogrel 75mg Sim 
   Não 
 
Ticagrelor (dose):       Sim         
Não                
 
Anticoagulação oral (dose):  
Sim 
Varfarina ___________              
Rivaroxabano ___________    
Dabigatrano __________           
Apixabano ___________     
Edoxabano ___________    
   Não
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REFERENCIAÇÃO PÓS-ALTA 
 
Cuidados Paliativos:     Sim 
       Não 
 
Follow-up Cardiologia:     Sim 
          Não 
 
Consulta de Medicina Interna:   Sim  
                                                         Não  
 
Médico de Família:      Sim 
               Não 
 
Outras especialidades:   Sim    
Não 
 
 
Data da alta: __/__/____
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OUTROS 
 
Dias de internamento por IC: último ano _____ 
    últimos 6 meses _____ 
    últimos 3 meses _____ 
último mês _____ 
 
Hospitalizações por IC:   último ano _____ 
    últimos 6 meses _____ 
    últimos 3 meses _____ 
último mês _____ 
 
Síndrome Cardio-Renal tipo 1
7
:  Sim 
                 Não  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nota 
7
 – “an increase ≥ 0.3 mg/dl in serum creatinine relative to the admission level for the purposes of the study” in 7th ADQI 
Consensus Conference.
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COMPLICAÇÕES APÓS ALTA 
 
Insuficiência Renal/Agravamento da função renal:  1 mês _____ 
       2 meses _____ 
       3 meses _____ 
       6 meses _____ 
       1 ano _____ 
 
Hospitalizações por qualquer causa (se sim diagnóstico):  1 mês _____ 
                2 meses _____ 
                 3 meses _____ 
 
Morte por qualquer causa (se sim diagnóstico):    1 mês _____ 
         2 meses _____ 
         3 meses _____ 
 
Morte por IC:    1 mês _____ 
     2 meses _____ 
     3 meses _____ 
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